Delgado F, Oteros R, Jimenez-Gomez E, Bravo Rey I, Bautista MD, Valverde Moyano R. Half bolus dose of intravenous abciximab is safe and effectiveinthesettingofacutestrokeendovasculartreatment.JNeurointerv 204. Heck DV, Brown MD. Carotid stenting and intracranial thrombectomy for treatment of acute stroke due to tandem occlusions with aggres- sive antiplatelet therapy may be associated with a high incidence of intracranial hemorrhage. J Neurointerv Surg. 2015;7:170 175. doi: 205. Ernst M, Butscheid F, Fiehler J, Wittkugel O, Alfke K, Jansen O, Petersen D, Koch C, Eckert B. Glycoprotein IIb/IIIa inhibitor bridg- ing and subsequent endovascular therapy in vertebrobasilar occlu- sion in 120 patients. Clin Neuroradiol. 2016;26:169 175. doi: 206. Dippel DW, Majoie CB, RoosYB, van der Lugt A, van Oostenbrugge RJ, vanZwamWH,LingsmaHF,KoudstaalPJ,TreurnietKM,vandenBergLA, et al; for the MR CLEAN Investigators. Influence of device choice on the Powers et al 2019 Guidelines for Management of AIS e409 effect of intra-arterial treatment for acute ischemic stroke in MR CLEAN (Multicenter Randomized Clinical Trial of Endovascular Treatment for Acute Ischemic Stroke in the Netherlands). Stroke. 2016;47:2574 2581. 207. The International Stroke Trial (IST): a randomised trial of aspirin, subcu- taneous heparin, both, or neither among 19435 patients with acute isch- aemic stroke: International Stroke Trial Collaborative Group. Lancet. 1997;349:1569 1581. 208. CAST (Chinese Acute Stroke Trial) Collaborative Group. CAST: ran- domised placebo-controlled trial of early aspirin use in 20,000 patients with acute ischaemic stroke. Lancet. 1997;349:1641 1649. 209. Sandercock PA, Counsell C, Tseng MC, Cecconi E. Oral antiplate- let therapy for acute ischaemic stroke. Cochrane Database Syst Rev. 210. Wang Y, Wang Y, Zhao X, Liu L, Wang D, Wang C, Wang C, Li H, Meng X, Cui L, et al; CHANCE Investigators. Clopidogrel with as- pirin in acute minor stroke or transient ischemic attack. N Engl J Med. 211.


Clopidogrel with as- pirin in acute minor stroke or transient ischemic attack. N Engl J Med. 211. Wang X, Zhao X, Johnston SC, Xian Y, Hu B, Wang C, Wang D, Liu L, Li H, Fang J, et al; CHANCE Investigators. Effect of clopidogrel with as- pirin on functional outcome in TIA or minor stroke: CHANCE substudy. 212. Pan Y, Wang Y, Wang Y. Author response: risks and benefits of clopidogrel-aspirin in minor stroke or TIA: time course analysis of CHANCE. Neurology. 2017;89:2121 2122. doi: 10.1212/WNL. 213. Wang Y, Pan Y, Zhao X, Li H, Wang D, Johnston SC, Liu L, MengX,WangA,WangC,etalY;onbehalfoftheCHANCEInvestigators. Clopidogrel With Aspirin in Acute Minor Stroke or Transient Ischemic Attack (CHANCE) Trial: one-year outcomes. Circulation. 2015;132:40 214. WangY, Zhao X, Lin J, Li H, Johnston SC, LinY, PanY, Liu L, Wang D, Wang C, et al; CHANCE Investigators. Association between CYP2C19 loss-of-function allele status and efficacy of clopidogrel for risk re- duction among patients with minor stroke or transient ischemic attack. 215. Jing J, Meng X, Zhao X, Liu L, Wang A, Pan Y, Li H, Wang D, Johnston SC, Wang Y, et al. Dual antiplatelet therapy in transient is- chemic attack and minor stroke with different infarction patterns: sub- group analysis of the CHANCE randomized clinical trial. JAMA Neurol. 216. Johnston SC, Easton JD, Farrant M, Barsan W, Conwit RA, Elm JJ, Kim AS, Lindblad AS, Palesch YY; Clinical Research Collaboration, Neurological Emergencies Treatment Trials Network, and the POINT Investigators. Clopidogrel and aspirin in acute ischemic stroke and high-risk TIA. N Engl J Med. 2018;379:215 225. doi: 217. Siebler M, Hennerici MG, Schneider D, von Reutern GM, Seitz RJ, R ther J, Witte OW, Hamann G, Junghans U, Villringer A, et al. Safety of Tirofiban in Acute Ischemic Stroke: the SaTIS trial. Stroke. 218.


Safety of Tirofiban in Acute Ischemic Stroke: the SaTIS trial. Stroke. 218. Pancioli AM, Broderick J, Brott T, Tomsick T, Khoury J, Bean J, del Zoppo G, Kleindorfer D, Woo D, Khatri P, et al; CLEAR Trial Investigators. The combined approach to lysis utilizing eptifiba- tide and rt-PA in acute ischemic stroke: the CLEAR stroke trial. Stroke. 219. Johnston SC, Amarenco P. Ticagrelor versus aspirin in acute stroke or transient ischemic attack. N Engl J Med. 2016;375:1395. doi: 220. Ciccone A, Motto C, Abraha I, Cozzolino F, Santilli I. Glycoprotein IIb- IIIa inhibitors for acute ischaemic stroke. Cochrane Database Syst Rev. 221. Adams HP Jr, Effron MB, Torner J, D valos A, Frayne J, Teal P, Leclerc J, Oemar B, Padgett L, Barnathan ES, et al; for the AbESTT-II Investigators. Emergency administration of abciximab for treatment of patients with acute ischemic stroke: results of an international phase III trial: Abciximab in Emergency Treatment of Stroke Trial (AbESTT-II). 222. Mokin M, Kass-Hout T, Kass-Hout O, Radovic V, Siddiqui AH, Levy EI, SnyderKV.Intravenousheparinforthetreatmentofintraluminalthrombus in patients with acute ischemic stroke: a case series. J Neurointerv Surg. 223. Vellimana AK, Kadkhodayan Y, Rich KM, Cross DT 3rd, Moran CJ, Zazulia AR, Lee JM, Chicoine MR, Dacey RG Jr, Derdeyn CP, et al. Symptomatic patients with intraluminal carotid artery thrombus: outcome with a strategy of initial anticoagulation. J Neurosurg. 2013;118:34 41. 224. Kate M, Gioia L, Buck B, Sivakumar L, Jeerakathil T, ShuaibA, Butcher K. Dabigatran therapy in acute ischemic stroke patients without atrial fibrillation. Stroke. 2015;46:2685 2687. doi: 10.1161/ Sisson A, Pandurengan R, Chen Z, et al. The Argatroban and Tissue-Type Plasminogen Activator Stroke Study: final results of a pilot safety study. 226.


The Argatroban and Tissue-Type Plasminogen Activator Stroke Study: final results of a pilot safety study. 226. Barreto AD, Ford GA, Shen L, Pedroza C, Tyson J, Cai C, Rahbar MH, Grotta JC; on behalf of the ARTSS-2 Investigators. Randomized, mul- ticenter trial of ARTSS-2 (Argatroban With Recombinant Tissue Plasminogen Activator for Acute Stroke). Stroke. 2017;48:1608 1616. 227. Gioia LC, Kate M, Sivakumar L, Hussain D, Kalashyan H, Buck B, Bussiere M, Jeerakathil T, Shuaib A, Emery D, et al. Early rivaroxaban use after cardioembolic stroke may not result in hemorrhagic trans- formation: a prospective magnetic resonance imaging study. Stroke. 228. Whiteley WN, Adams HP Jr, Bath PM, Berge E, Sandset PM, Dennis M, Murray GD, Wong KS, Sandercock PA. Targeted use of heparin, hepa- rinoids, or low-molecular-weight heparin to improve outcome after acute ischaemic stroke: an individual patient data meta-analysis of randomised controlled trials. Lancet Neurol. 2013;12:539 545. doi: 229. Sandercock PA, Counsell C, Kane EJ. Anticoagulants for acute isch- aemic stroke. Cochrane Database Syst Rev. 2015:CD000024. 230. Yi X, Lin J, Wang C, Zhang B, Chi W. Low-molecular-weight heparin is more effective than aspirin in preventing early neurologic deteri- oration and improving six-month outcome. J Stroke Cerebrovasc Dis. 231. Chang TS, Jensen MB. Haemodilution for acute ischaemic stroke. Cochrane Database Syst Rev. 2014:CD000103. 232. Ginsberg MD, Palesch YY, Hill MD, Martin RH, Moy CS, Barsan WG, Waldman BD, Tamariz D, Ryckborst KJ; ALIAS and Neurological Emergencies Treatment Trials (NETT) Investigators. High-dose al- bumin treatment for acute ischaemic stroke (ALIAS) part 2: a ran- domised, double-blind, phase 3, placebo-controlled trial. Lancet Neurol. ALIAS Parts 1 and 2 and NETT Investigators. ALIAS (Albumin in Acute Ischemic Stroke) trials: analysis of the combined data from parts 1 and 2. 234.


ALIAS (Albumin in Acute Ischemic Stroke) trials: analysis of the combined data from parts 1 and 2. 234. Guluma KZ, Liebeskind DS, Raman R, Rapp KS, Ernstrom KB, Alexandrov AV, Shahripour RB, Barlinn K, Starkman S, Grunberg ID, et al. Feasibility and safety of using external counterpulsation to augment cerebral blood flow in acute ischemic stroke: the Counterpulsation to UpgradeForwardFlowinStroke(CUFFS)Trial.JStrokeCerebrovascDis. 235. Saver JL, Starkman S, Eckstein M, Stratton SJ, Pratt FD, Hamilton S, Conwit R, Liebeskind DS, Sung G, Kramer I, et al; FAST- MAG Investigators and Coordinators. Prehospital use of magnesium sulfate as neuroprotection in acute stroke. N Engl J Med. 2015;372:528 236. Lapchak PA. Taking a light approach to treating acute ischemic stroke patients: transcranial near-infrared laser therapy translational science. Ann Med. 2010;42:576 586. doi: 10.3109/07853890.2010.532811 237. StemerAB, Huisa BN, Zivin JA. The evolution of transcranial laser therapy 238. Zivin JA, Albers GW, Bornstein N, Chippendale T, Dahlof B, Devlin T, Fisher M, Hacke W, Holt W, Ilic S, et al; for the NeuroThera Effectiveness and Safety Trial-2 Investigators. Effectiveness and safety of transcranial laser therapy for acute ischemic stroke. Stroke. 2009;40:1359 1364. doi: 239. Hacke W, Schellinger PD, Albers GW, Bornstein NM, Dahlof BL, Fulton R, Kasner SE, Shuaib A, Richieri SP, Dilly SG, et al; for the NEST 3 Committees and Investigators. Transcranial laser therapy in acute stroke treatment: results of Neurothera Effectiveness and Safety Trial 3, a phase III clinical end point device trial. Stroke. 2014;45:3187 240. Anderson CS, Arima H, Lavados P, Billot L, Hackett ML, Olavarr a VV, Mu oz Venturelli P, Brunser A, Peng B, Cui L, et al; HeadPoSTInvestigatorsandCoordinators.Cluster-randomized,crossover trial of head positioning in acute stroke. N Engl J Med. 2017;376:2437 241.


Anderson CS, Arima H, Lavados P, Billot L, Hackett ML, Olavarr a VV, Mu oz Venturelli P, Brunser A, Peng B, Cui L, et al; HeadPoSTInvestigatorsandCoordinators.Cluster-randomized,crossover trial of head positioning in acute stroke. N Engl J Med. 2017;376:2437 241. Alexandrov AW, Tsivgoulis G, Hill MD, Liebeskind DS, Schellinger P, Ovbiagele B, Arthur AS, Caso V, Nogueira RG, Hemphill JC 3rd, et al. HeadPoST: rightly positioned, or flat out wrong? Neurology. 242. Olavarr a VV, Lavados PM, Mu oz-Venturelli P, Gonz lez F, Gaete J, Martins S, Arima H, Anderson CS, Brunser AM. Flat-head positioning increases cerebral blood flow in anterior circulation acute ischemic stroke: a cluster randomized phase IIb trial. Int J Stroke. 2018;13:600 243. Stead LG, Gilmore RM, Vedula KC, Weaver AL, Decker WW, Brown RD Jr. Impact of acute blood pressure variability on is- chemic stroke outcome. Neurology. 2006;66:1878 1881. doi: 244. Horn J, de Haan RJ, Vermeulen M, Limburg M. Very Early Nimodipine Use in Stroke (VENUS): a randomized, double-blind, placebo-controlled trial. Stroke. 2001;32:461 465. doi: 10.1161/01.str.32.2.461 245. Schrader J, L ders S, Kulschewski A, Berger J, Zidek W, Treib J, Einh upl K, Diener HC, Dominiak P; on behalf of the Acute Candesartan Cilexetil Therapy in Stroke Survivors Study Group. The ACCESS Study: evaluation of Acute Candesartan Cilexetil Therapy in Stroke Survivors. 246. Potter JF, Robinson TG, Ford GA, Mistri A, James M, Chernova J, Jagger C. Controlling Hypertension and Hypotension Immediately Post- Stroke (CHHIPS): a randomised, placebo-controlled, double-blind pilot 247. Robinson TG, Potter JF, Ford GA, Bulpitt CJ, Chernova J, Jagger C, James MA, Knight J, Markus HS, Mistri AK, et al; COSSACS Investigators. Effects of antihypertensive treatment after acute stroke in the Continue or Stop Post-Stroke Antihypertensives Collaborative Study (COSSACS): a prospective, randomised, open, blinded-endpoint trial. Lancet Neurol. 2010;9:767 775. doi: 10.1016/S1474-4422(10)70163-0 248.


Effects of antihypertensive treatment after acute stroke in the Continue or Stop Post-Stroke Antihypertensives Collaborative Study (COSSACS): a prospective, randomised, open, blinded-endpoint trial. Lancet Neurol. 2010;9:767 775. doi: 10.1016/S1474-4422(10)70163-0 248. He J, Zhang Y, Xu T, Zhao Q, Wang D, Chen CS, Tong W, Liu C, Xu T, Ju Z, et al; CATIS Investigators. Effects of immediate blood pressure reduction on death and major disability in patients with acute ischemic stroke: the CATIS randomized clinical trial. JAMA. 2014;311:479 489. 249. ENOS Trial Investigators, Bath PM, Woodhouse L, Scutt P, Krishnan K, Wardlaw JM, Bereczki D, Sprigg N, Berge E, Beridze M, Caso V, et al. Efficacy of nitric oxide, with or without continuing antihypertensive treat- ment, for management of high blood pressure in acute stroke (ENOS): a partial-factorial randomised controlled trial. Lancet. 2015;385:617 628. 250. Kaste M, Fogelholm R, Eril T, Palom ki H, Murros K, Rissanen A, Sarna S.A randomized, double-blind, placebo-controlled trial of nimodip- ine in acute ischemic hemispheric stroke. Stroke. 1994;25:1348 1353. 251. Wahlgren NG, MacMahon DG, De Keyser J, Indredavik B, Ryman T. The Intravenous Nimodipine West European Trial (INWEST) of nimodip- ine in the treatment of acute ischemic stroke. Cerebrovasc Dis. 1994;4:204 210. 252. Eveson DJ, Robinson TG, Potter JF. Lisinopril for the treatment of hyper- tension within the first 24 hours of acute ischemic stroke and follow-up. Am J Hypertens. 2007;20:270 277. doi: 10.1016/j.amjhyper.2006.08.005 253. Bath PM, Martin RH, PaleschY, Cotton D,Yusuf S, Sacco R, Diener HC, Toni D, Estol C, Roberts R; for the PRoFESS Study Group. Effect of telmisartan on functional outcome, recurrence, and blood pressure in patients with acute mild ischemic stroke: a PRoFESS subgroup analysis. 254.


Effect of telmisartan on functional outcome, recurrence, and blood pressure in patients with acute mild ischemic stroke: a PRoFESS subgroup analysis. 254. Sandset EC, Bath PM, Boysen G, Jatuzis D, K rv J, L ders S, Murray GD, Richter PS, Roine RO, Ter nt A, et al; SCAST Study Group. The angiotensin-receptor blocker candesartan for treatment of acute stroke (SCAST): a randomised, placebo-controlled, double-blind trial. 255. Bath PM, Krishnan K. Interventions for deliberately altering blood pres- sure in acute stroke. Cochrane Database Syst Rev. 2014:CD000039. 256. Oh MS, Yu KH, Hong KS, Kang DW, Park JM, Bae HJ, Koo J, Lee J, Lee BC; Valsartan Efficacy oN modesT blood pressUre REduction in acute ischemic stroke (VENTURE) study group. Modest blood pressure reduction with valsartan in acute ischemic stroke: a prospective, random- ized, open-label, blinded-end-point trial. Int J Stroke. 2015;10:745 751. 257. LeeM,OvbiageleB,HongKS,WuYL,LeeJE,RaoNM,FengW,SaverJL. Effect of blood pressure lowering in early ischemic stroke: meta-analysis. 258. Woodhouse L, Scutt P, Krishnan K, Berge E, Gommans J, Ntaios G, Wardlaw J, Sprigg N, Bath PM; on behalf of the ENOS Investigators. Effect of hyperacute administration (within 6 hours) of transdermal glyc- eryl trinitrate, a nitric oxide donor, on outcome after stroke: subgroup analysis of the Efficacy of Nitric Oxide in Stroke (ENOS) Trial. Stroke. 259. Rai N, Prasad K, Bhatia R, Vibha D, Singh MB, Rai VK, Kumar A. Development and implementation of acute stroke care pathway in a ter- tiary care hospital in India: a cluster-randomized study. Neurol India. 260. Middleton S, McElduff P, Ward J, Grimshaw JM, Dale S, D Este C, Drury P, Griffiths R, Cheung NW, Quinn C, et al; QASC Trialists Group. Implementation of evidence-based treatment protocols to manage fever, hyperglycaemia, and swallowing dysfunction in acute stroke (QASC): a cluster randomised controlled trial. Lancet. 2011;378:1699 1706. doi: 261.


Implementation of evidence-based treatment protocols to manage fever, hyperglycaemia, and swallowing dysfunction in acute stroke (QASC): a cluster randomised controlled trial. Lancet. 2011;378:1699 1706. doi: 261. Miles A, Zeng IS, McLauchlan H, Huckabee ML. Cough reflex testing in Dysphagia following stroke: a randomized controlled trial. J Clin Med 262. Joundi RA, Martino R, Saposnik G, Giannakeas V, Fang J, Kapral MK. Predictorsandoutcomesofdysphagiascreeningafteracuteischemicstroke. 263. S rensen RT, Rasmussen RS, Overgaard K, Lerche A, Johansen AM, Lindhardt T. Dysphagia screening and intensified oral hygiene re- duce pneumonia after stroke. J Neurosci Nurs. 2013;45:139 146. doi: 264. Brady M, Furlanetto D, Hunter RV, Lewis S, Milne V. Staff-led interven- tions for improving oral hygiene in patients following stroke. Cochrane Database Syst Rev. 2006:CD003864. 265. Wagner C, Marchina S, Deveau JA, Frayne C, Sulmonte K, Kumar S. Risk of stroke-associated pneumonia and oral hygiene. Cerebrovasc Dis. 266. Dennis M, Lewis S, Cranswick G, Forbes J; FOOD Trial Collaboration. FOOD: a multicentre randomised trial evaluating feeding policies in patients admitted to hospital with a recent stroke. Health Technol Assess. 2006;10:iii iv, ix. 267. Geeganage C, Beavan J, Ellender S, Bath PM. Interventions for dysphagia and nutritional support in acute and subacute stroke. Cochrane Database Syst Rev. 2012;10:CD000323. doi: 10.1002/14651858.CD000323.pub2 268. Dennis M, Sandercock P, Reid J, Graham C, Forbes J, Murray G; CLOTS (Clots in Legs Or sTockings after Stroke) Trials Collaboration. Effectiveness of intermittent pneumatic compression in reduction of risk of deep vein thrombosis in patients who have had a stroke (CLOTS 3): a multicentre randomised controlled trial. Lancet. 2013;382:516 524. doi: 269. Dennis M, Caso V, Kappelle LJ, Pavlovic A, Sandercock P; European Stroke Organisation. European Stroke Organisation (ESO) guide- lines for prophylaxis for venous thromboembolism in immobile patients with acute ischaemic stroke. Eur Stroke J. 2016;1:6 19. doi: 270.


European Stroke Organisation (ESO) guide- lines for prophylaxis for venous thromboembolism in immobile patients with acute ischaemic stroke. Eur Stroke J. 2016;1:6 19. doi: 270. Meader N, Moe-Byrne T, Llewellyn A, Mitchell AJ. Screening for poststroke major depression: a meta-analysis of diagnostic va- lidity studies. J Neurol Neurosurg Psychiatry. 2014;85:198 206. doi: 271. Berg A, L nnqvist J, Palom ki H, Kaste M. Assessment of depression after stroke: a comparison of different screening instruments. Stroke. 272. Kang HJ, Stewart R, Kim JM, Jang JE, Kim SY, Bae KY, Kim SW, Shin IS, Park MS, Cho KH, et al. Comparative validity of depression assessment scales for screening poststroke depression. J Affect Disord. 273. WilliamsLS,KroenkeK,BakasT,PlueLD,BrizendineE,TuW,HendrieH. Caremanagementofpoststrokedepression:arandomized,controlledtrial. 274. Westendorp WF, Vermeij JD, Zock E, Hooijenga IJ, Kruyt ND, Bosboom HJ, Kwa VI, Weisfelt M, Remmers MJ, ten Houten R, et al; PASS investigators. The Preventive Antibiotics in Stroke Study (PASS): a pragmatic randomised open-label masked endpoint clinical trial. 275. Kalra L, Irshad S, Hodsoll J, Simpson M, Gulliford M, Smithard D, Patel A, Rebollo-Mesa I; STROKE-INF Investigators. Prophylactic anti- biotics after acute stroke for reducing pneumonia in patients with dys- phagia (STROKE-INF): a prospective, cluster-randomised, open-label, masked endpoint, controlled clinical trial. Lancet. 2015;386:1835 1844. Powers et al 2019 Guidelines for Management of AIS e411 276. Liu L, Xiong XY, Zhang Q, Fan XT, Yang QW. The efficacy of prophy- lactic antibiotics on post-stroke infections: an updated systematic review and meta-analysis. Sci Rep. 2016;6:36656. doi: 10.1038/srep36656 277. Zheng F, Spreckelsen NV, Zhang X, Stavrinou P, Timmer M, Dohmen C, Goldbrunner R, Cao F, Zhang Q, Ran Q, et al. Should preventive antibiot- ics be used in patients with acute stroke? A systematic review and meta- analysis of randomized controlled trials. PLoS One. 2017;12:e0186607. 278.


A systematic review and meta- analysis of randomized controlled trials. PLoS One. 2017;12:e0186607. 278. Vermeij JD, Westendorp WF, Dippel DW, van de Beek D, Nederkoorn PJ. Antibiotic therapy for preventing infections in people with acute stroke. Cochrane Database Syst Rev. 2018;1:CD008530. doi: 279. AVERT Trial Collaboration Group, Bernhardt J, Langhorne P, Lindley RI, ThriftAG,ElleryF,CollierJ,ChurilovL,MoodieM,DeweyH,DonnanG. Efficacy and safety of very early mobilisation within 24 h of stroke onset (AVERT): a randomised controlled trial. Lancet. 2015;386:46 55. 280. Vahedi K, Hofmeijer J, Juettler E, Vicaut E, George B, Algra A, Amelink GJ, Schmiedeck P, Schwab S, Rothwell PM, Bousser MG, van der Worp HB, Hacke W; DECIMAL, DESTINY, and HAMLET Investigators. Early decompressive surgery in malignant infarc- tion of the middle cerebral artery: a pooled analysis of three ran- domised controlled trials. Lancet Neurol. 2007;6:215 222. doi: 281. Christensen MS, Paulson OB, Olesen J, Alexander SC, Skinhoj E, Dam WH, Lassen NA. Cerebral apoplexy (stroke) treated with or without prolonged artificial hyperventilation, 1: cerebral circu- lation, clinical course, and cause of death. Stroke. 1973;4:568 631. doi: 282. Ausina A, B guena M, Nadal M, Manrique S, Ferrer A, Sahuquillo J, Garnacho A. Cerebral hemodynamic changes during sustained hypocap- nia in severe head injury: can hyperventilation cause cerebral ischemia? Acta Neurochir Suppl. 1998;71:1 4. doi: 10.1007/978-3-7091-6475-4_1 283. Steiner LA, Balestreri M, Johnston AJ, Czosnyka M, Coles JP, Chatfield DA, Smielewski P, Pickard JD, Menon DK. Sustained mod- erate reductions in arterial CO2 after brain trauma time-course of cere- bral blood flow velocity and intracranial pressure. Intensive Care Med. 284. Carrera E, Steiner LA, Castellani G, Smielewski P, Zweifel C, Haubrich C, Pickard JD, Menon DK, Czosnyka M. Changes in cerebral compartmental compliances during mild hypocapnia in patients with traumatic brain injury. J Neurotrauma. 2011;28:889 896. doi: 285.


Carrera E, Steiner LA, Castellani G, Smielewski P, Zweifel C, Haubrich C, Pickard JD, Menon DK, Czosnyka M. Changes in cerebral compartmental compliances during mild hypocapnia in patients with traumatic brain injury. J Neurotrauma. 2011;28:889 896. doi: 285. Muizelaar JP, Marmarou A, Ward JD, Kontos HA, Choi SC, Becker DP, Gruemer H, Young HF. Adverse effects of prolonged hyperventilation in patients with severe head injury: a randomized clinical trial. J Neurosurg. 286. Wan YH, Nie C, Wang HL, Huang CY. Therapeutic hypothermia (differ- ent depths, durations, and rewarming speeds) for acute ischemic stroke: a meta-analysis. J Stroke Cerebrovasc Dis. 2014;23:2736 2747. doi: 287. Maciel CB, Sheth KN. Malignant MCA stroke: an update on surgical decompression and future directions. Curr Atheroscler Rep. 2015;17:40. 288. Yang MH, Lin HY, Fu J, Roodrajeetsing G, Shi SL, Xiao SW. Decompressive hemicraniectomy in patients with malignant middle ce- rebral artery infarction: a systematic review and meta-analysis. Surgeon. 289. Agarwalla PK, Stapleton CJ, Ogilvy CS. Craniectomy in acute is- chemic stroke. Neurosurgery. 2014;74(suppl 1):S151 S162. doi: 290. Alexander P, Heels-Ansdell D, Siemieniuk R, Bhatnagar N, Chang Y, FeiY, ZhangY, McLeod S, Prasad K, Guyatt G. Hemicraniectomy versus medical treatment with large MCA infarct: a review and meta-analysis. BMJ Open. 2016;6:e014390. doi: 10.1136/bmjopen-2016-014390 291. Sundseth J, Sundseth A, Jacobsen EA, Pripp AH, Sorteberg W, Altmann M, Lindegaard KF, Berg-Johnsen J, Thommessen B. Predictors of early in-hospital death after decompressive craniectomy in swollen middle cerebral artery infarction. Acta Neurochir (Wien). 2017;159:301 292. Suyama K, Horie N, Hayashi K, Nagata I. Nationwide survey of decompressive hemicraniectomy for malignant middle cerebral ar- tery infarction in Japan. World Neurosurg. 2014;82:1158 1163. doi: 293. Yu JW, Choi JH, Kim DH, Cha JK, Huh JT. Outcome following decom- pressive craniectomy for malignant middle cerebral artery infarction in patients older than 70 years old.


Outcome following decom- pressive craniectomy for malignant middle cerebral artery infarction in patients older than 70 years old. J Cerebrovasc Endovasc Neurosurg. 294. J ttler E, Unterberg A, Woitzik J, B sel J, Amiri H, SakowitzOW,GondanM,SchillerP,LimprechtR,LuntzS,etal;DESTINY II Investigators. Hemicraniectomy in older patients with extensive mid- dle-cerebral-artery stroke. N Engl J Med. 2014;370:1091 1100. doi: 295. Zhao J, Su YY, Zhang Y, Zhang YZ, Zhao R, Wang L, Gao R, Chen W, Gao D. Decompressive hemicraniectomy in malignant middle cerebral ar- tery infarct: a randomized controlled trial enrolling patients up to 80 years old. Neurocrit Care. 2012;17:161 171. doi: 10.1007/s12028-012-9703-3 296. Raco A, Caroli E, Isidori A, Salvati M. Management of acute cerebellar infarction: one institution s experience. Neurosurgery. 2003;53:1061 297. Mostofi K. Neurosurgical management of massive cerebellar in- farct outcome in 53 patients. Surg Neurol Int. 2013;4:28. doi: 298. Heidenreich JO, Hsu D, Wang G, Jesberger JA, Tarr RW, Zaidat OO, Sunshine JL. Magnetic resonance imaging results can affect therapy decisions in hyperacute stroke care. Acta Radiol. 2008;49:550 557. doi: 299. North American Symptomatic Carotid Endarterectomy Trial Collaborators, Barnett HJM, Taylor DW, Haynes RB, Sackett DL, PeerlessSJ,FergusonGG,FoxAJ,RankinRN,HachinskiVC,WiebersDO, et al. Beneficial effect of carotid endarterectomy in symptomatic patients with high-grade carotid stenosis. N Engl J Med. 1991;325:445 453. doi: 300. Randomised trial of endarterectomy for recently symptomatic carotid stenosis: final results of the MRC European Carotid Surgery Trial (ECST). Lancet. 1998;351:1379 1387. 301. Amarenco P, Bogousslavsky J, Callahan A 3rd, Goldstein LB, Hennerici M, Rudolph AE, Sillesen H, Simunovic L, Szarek M, Welch KM, et al; Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Investigators. High-dose atorvastatin after stroke or transient ischemic attack. N Engl J Med. 2006;355:549 302.


High-dose atorvastatin after stroke or transient ischemic attack. N Engl J Med. 2006;355:549 302. Diener HC, Cunha L, Forbes C, Sivenius J, Smets P, Lowenthal A. European Stroke Prevention Study, 2: dipyridamole and acetylsalicylic acid in the secondary prevention of stroke. J Neurol Sci. 1996;143:1 13. 303. CAPRIE Steering Committee. A randomised, blinded, trial of clopido- grel versus aspirin in patients at risk of ischaemic events (CAPRIE): CAPRIE Steering Committee. Lancet. 1996;348:1329 1339. doi: 304. Sacco RL, Diener HC, Yusuf S, Cotton D, Ounpuu S, Lawton WA, Palesch Y, Martin RH, Albers GW, Bath P, et al; PRoFESS Study Group. Aspirin and extended-release dipyridamole versus clopido- grel for recurrent stroke. N Engl J Med. 2008;359:1238 1251. doi: 305. SALT Collaborative Group. Swedish Aspirin Low-Dose Trial (SALT) of 75 mg aspirin as secondary prophylaxis after cerebrovascular ischaemic events. Lancet. 1991;338:1345 1349. 306. PROGRESS Collaborative Group. Randomised trial of a perindopril- based blood-pressure-lowering regimen among 6,105 individuals with previous stroke or transient ischaemic attack. Lancet. 2001;358:1033 307. Burke JF, Gelb DJ, Quint DJ, Morgenstern LB, Kerber KA. The impact of MRI on stroke management and outcomes: a systematic review. J Eval Clin Pract. 2013;19:987 993. doi: 10.1111/jep.12011 308. Wardlaw J, Brazzelli M, Miranda H, Chappell F, McNamee P, Scotland G, Quayyum Z, Martin D, Shuler K, Sandercock P, et al. An assessment of the cost-effectiveness of magnetic resonance, including diffusion- weighted imaging, in patients with transient ischaemic attack and minor stroke: a systematic review, meta-analysis and economic evaluation. Health Technol Assess. 2014;18:1 368, v vi. doi: 10.3310/hta18270 309. Ertl-Wagner B, Brandt T, Seifart C, Forsting M. Diagnostic and thera- peutic consequences of repeat brain imaging and follow-up vascular im- aging in stroke patients. AJNR Am J Neuroradiol. 1999;20:37 42. 310.


Ertl-Wagner B, Brandt T, Seifart C, Forsting M. Diagnostic and thera- peutic consequences of repeat brain imaging and follow-up vascular im- aging in stroke patients. AJNR Am J Neuroradiol. 1999;20:37 42. 310. Schneider LB, Libman RB, Kanner R. Utility of repeat brain imaging in stroke. AJNR Am J Neuroradiol. 1996;17:1259 1263. 311. S ndergaard L, Kasner SE, Rhodes JF, Andersen G, Iversen HK, Nielsen-KudskJE,SettergrenM,Sj strandC,RoineRO,Hildick-SmithD, et al; Gore REDUCE Clinical Study Investigators. Patent foramen ovale closure or antiplatelet therapy for cryptogenic stroke. N Engl J Med. 312. Mas JL, Derumeaux G, Guillon B, Massardier E, Hosseini H, Mechtouff L, Arquizan C, B jot Y, Vuillier F, Detante O, et al; CLOSE Investigators. Patent foramen ovale closure or anticoagulation vs. antiplatelets after stroke. N Engl J Med. 2017;377:1011 1021. doi: 313. Carroll JD, Saver JL, Thaler DE, Smalling RW, Berry S, MacDonald LA, Marks DS, Tirschwell DL; RESPECT Investigators. Closure of patent foramen ovale versus medical therapy after cryptogenic stroke. N Engl J 314. Saver JL, Carroll JD, Thaler DE, Smalling RW, MacDonald LA, Marks DS, Tirschwell DL; RESPECT Investigators. Long-term out- comes of patent foramen ovale closure or medical therapy after stroke. N Engl J Med. 2017;377:1022 1032. doi: 10.1056/NEJMoa1610057 315. Meier B, Kalesan B, Mattle HP, Khattab AA, Hildick-Smith D, Dudek D, AndersenG,IbrahimR,SchulerG,WaltonAS,etal;PCTrialInvestigators. Percutaneous closure of patent foramen ovale in cryptogenic embolism. N Engl J Med. 2013;368:1083 1091. doi: 10.1056/NEJMoa1211716 316. Furlan AJ, Reisman M, Massaro J, Mauri L, Adams H, Albers GW, Felberg R, Herrmann H, Kar S, Landzberg M, et al; CLOSURE I Investigators. Closure or medical therapy for cryptogenic stroke with patent foramen ovale. N Engl J Med. 2012;366:991 999. doi: 317. Lee PH, Song JK, Kim JS, Heo R, Lee S, Kim DH, Song JM, Kang DH, Kwon SU, Kang DW, et al.


Lee PH, Song JK, Kim JS, Heo R, Lee S, Kim DH, Song JM, Kang DH, Kwon SU, Kang DW, et al. cryptogenic stroke and high-risk patent foramen ovale: the DEFENSE-PFO Trial. J Am Coll Cardiol. 318. Turc G, Calvet D, Guerin P, Sroussi M, Chatellier G, Mas JL, CLOSE Investigators. Closure, anticoagulation, or antiplatelet therapy for crypto- genic stroke with patent foramen ovale: systematic review of randomized trials, sequential meta-analysis, and new insights from the CLOSE Study. J Am Heart Assoc. 2018;7:e008356. doi: 10.1161/JAHA.117.008356 319. Mir H, Siemieniuk RAC, Ge L, Foroutan F, Fralick M, Syed T, Lopes LC, Kuijpers T, Mas JL, Vandvik PO, et al. Patent foramen ovale closure, antiplatelet therapy or anticoagulation in patients with patent foramen ovale and cryptogenic stroke: a systematic review and network meta- analysis incorporating complementary external evidence. BMJ Open. 320. Qiu B, Cai Y, Wang D, Lin J, Fan Y. Closure versus medical therapy for patent foramen ovale in patients with cryptogenic stroke: an updated meta-analysis of randomized controlled trials. J Stroke Cerebrovasc Dis. 321. Giacoppo D, Caronna N, Frangieh AH, Michel J, And G, Tarantini G, Kasel AM, Capodanno D, Byrne RA. Long-term effectiveness and safety of transcatheter closure of patent foramen ovale compared with antithrom- botic therapy alone: a meta-analysis of six randomised clinical trials and 3,560 patients with reconstructed time-to-event data. EuroIntervention. 322. Niu X, Ou-Yang G, Yan PF, Huang SL, Zhang ZT, Zhang ZH. Closure of patent foramen ovale for cryptogenic stroke patients: an updated systematic review and meta-analysis of randomized trials. J Neurol. 323. Li J, Liu J, Liu M, Zhang S, Hao Z, Zhang J, Zhang C. Closure versus medical therapy for preventing recurrent stroke in patients with patent foramen ovale and a history of cryptogenic stroke or transient ischemic attack. Cochrane Database Syst Rev.


Li J, Liu J, Liu M, Zhang S, Hao Z, Zhang J, Zhang C. Closure versus medical therapy for preventing recurrent stroke in patients with patent foramen ovale and a history of cryptogenic stroke or transient ischemic attack. Cochrane Database Syst Rev. 2015:CD009938. 324. McIntyre WF, Spence J, Belley-Cote EP. Assessing the quality of ev- idence supporting patent foramen ovale closure over medical therapy after cryptogenic stroke. Eur Heart J. 2018;39:3618 3619. doi: 325. Ois A, Cuadrado-Godia E, Rodr guez-Campello A, Jimenez-Conde J, Roquer J. High risk of early neurological recurrence in symptomatic ca- rotid stenosis. Stroke. 2009;40:2727 2731. doi: 10.1161/STROKEAHA. 326. De Rango P, Brown MM, Chaturvedi S, Howard VJ, Jovin T, Mazya MV, Paciaroni M, Manzone A, Farchioni L, Caso V. Summary of evidence on early carotid intervention for recently symptomatic stenosis based on meta-analysis of current risks. Stroke. 2015;46:3423 3436. doi: Horgan G, Kyne L, Moroney J, McCormack PM, et al. Stroke recur- rence within the time window recommended for carotid endarterectomy. 328. Johansson EP, Arnerl v C, Wester P. Risk of recurrent stroke before ca- rotid endarterectomy: the ANSYSCAP study. Int J Stroke. 2013;8:220 329. Str mberg S, Nordanstig A, Bentzel T, sterberg K, Bergstr m GM. Risk of early recurrent stroke in symptomatic carotid stenosis. Eur J Vasc Endovasc Surg. 2015;49:137 144. doi: 10.1016/j.ejvs.2014.11.004 330. Kazandjian C, Kretz B, Lemogne B,Aboa Eboul C, B jotY, Steinmetz E. Influence of the type of cerebral infarct and timing of intervention in the early outcomes after carotid endarterectomy for symptomatic stenosis. J Vasc Surg. 2016;63:1256 1261. doi: 10.1016/j.jvs.2015.10.097 331. Azzini C, Gentile M, De Vito A, Traina L, Sette E, Fainardi E, Mascoli F, Casetta I. Very early carotid endarterectomy after intrave- nous thrombolysis. Eur J Vasc Endovasc Surg. 2016;51:482 486. doi: 332.


Very early carotid endarterectomy after intrave- nous thrombolysis. Eur J Vasc Endovasc Surg. 2016;51:482 486. doi: 332. Adachi K, Sadato A, Hayakawa M, Maeda S, Hirose Y. Acute carotid ar- tery stenting in symptomatic high-grade cervical carotid artery stenosis. Neurosurg Rev. 2017;40:45 51. doi: 10.1007/s10143-016-0737-4 333. Vasconcelos V, Cassola N, da Silva EM, Baptista-Silva JC. Immediate versus delayed treatment for recently symptomatic carotid ar- tery stenosis. Cochrane Database Syst Rev. 2016;9:CD011401. doi: Taylor DW, Haynes RB, Finan JW, Hachinski VC, et al. The North American Symptomatic Carotid Endarterectomy Trial: surgical results in 335. Chimowitz MI, Lynn MJ, Howlett-Smith H, Stern BJ, Hertzberg VS, Frankel MR, Levine SR, Chaturvedi S, Kasner SE, Benesch CG, et al; Warfarin-Aspirin Symptomatic Intracranial Disease Trial Investigators. Comparison of warfarin and aspirin for symptomatic intracra- nial arterial stenosis. N Engl J Med. 2005;352:1305 1316. doi: 336. Chimowitz MI, Lynn MJ, Derdeyn CP, Turan TN, Fiorella D, Lane BF, Janis LS, Lutsep HL, Barnwell SL, Waters MF, et al; SAMMPRIS Trial Investigators. Stenting versus aggressive medical therapy for in- tracranial arterial stenosis. N Engl J Med. 2011;365:993 1003. doi: 337. Derdeyn CP, Chimowitz MI, Lynn MJ, Fiorella D, Turan TN, Janis LS, Montgomery J, Nizam A, Lane BF, Lutsep HL, et al; Stenting and Aggressive Medical Management for Preventing Recurrent Stroke in Intracranial Stenosis Trial Investigators. Aggressive medical treatment with or without stenting in high-risk patients with intracranial artery stenosis (SAMMPRIS): the final results of a randomised trial. Lancet. 338. Lutsep HL, Barnwell SL, Larsen DT, Lynn MJ, Hong M, Turan TN, Derdeyn CP, Fiorella D, Janis LS, Chimowitz MI; for the SAMMPRIS Investigators. Outcome in patients previously on antithrombotic therapy in the SAMMPRIS trial: subgroup analysis. Stroke. 2015;46:775 779. 339.


Outcome in patients previously on antithrombotic therapy in the SAMMPRIS trial: subgroup analysis. Stroke. 2015;46:775 779. 339. Chaturvedi S, Turan TN, Lynn MJ, Derdeyn CP, Fiorella D, Janis LS, Chimowitz MI; for the SAMMPRIS Trial Investigators. Do patient char- acteristics explain the differences in outcome between medically treated patients in SAMMPRIS and WASID? Stroke. 2015;46:2562 2567. doi: 340. Kallm nzer B, Breuer L, Kahl N, Bobinger T, Raaz-Schrauder D, Huttner HB, Schwab S, K hrmann M. Serious cardiac arrhythmias after stroke: incidence, time course, and predictors: a systematic, prospec- tive analysis. Stroke. 2012;43:2892 2897. doi: 10.1161/STROKEAHA. 341. Fern ndez-Men ndez S, Garc a-Santiago R, Vega-Primo A, Gonz lez Nafr a N, Lara-Lezama LB, Redondo-Robles L, Montes-Montes M, Riveira-Rodr guez MC, Tejada-Garc a J. Cardiac arrhythmias in stroke unit patients: evaluation of the cardiac monitoring data. Neurologia. 2016;31:289 295. doi: 10.1016/j.nrl.2015.03.013 342. EAFT (European Atrial Fibrillation Trial) Study Group. Secondary prevention in non-rheumatic atrial fibrillation after transient ischaemic attack or minor stroke. Lancet. 1993;342:1255 1262. 343. Sposato LA, Cipriano LE, Saposnik G, Ru z Vargas E, Riccio PM, Hachinski V. Diagnosis of atrial fibrillation after stroke and transient ischaemic attack: a systematic review and meta-analysis. Lancet Neurol. 344. Sanna T, Diener HC, Passman RS, Di Lazzaro V, Bernstein RA, Morillo CA, Rymer MM, Thijs V, Rogers T, Beckers F, et al; CRYSTAL AF Investigators. Cryptogenic stroke and underlying atrial fibrillation. N Engl J Med. 2014;370:2478 2486. doi: 10.1056/NEJMoa1313600 345. Brachmann J, Morillo CA, Sanna T, Di Lazzaro V, Diener HC, Bernstein RA, Rymer M, Ziegler PD, Liu S, Passman RS. Uncovering atrial fibrillation beyond short-term monitoring in cryptogenic stroke patients: three-year results from the Cryptogenic Stroke and Underlying Powers et al 2019 Guidelines for Management of AIS e413 Atrial Fibrillation Trial. Circ Arrhythm Electrophysiol. 2016;9:e003333. 346.


Uncovering atrial fibrillation beyond short-term monitoring in cryptogenic stroke patients: three-year results from the Cryptogenic Stroke and Underlying Powers et al 2019 Guidelines for Management of AIS e413 Atrial Fibrillation Trial. Circ Arrhythm Electrophysiol. 2016;9:e003333. 346. Wachter R, Gr schel K, Gelbrich G, Hamann GF, Kermer P, LimanJ,SeegersJ,WasserK,SchulteA,J rriesF,etal;Find-AFRANDOMISED Investigators and Coordinators. Holter-electrocardiogram-monitoring in patients with acute ischaemic stroke (Find-AFrandomised): an open- label randomised controlled trial. Lancet Neurol. 2017;16:282 290. doi: 347. Martin DT, Bersohn MM, Waldo AL, Wathen MS, Choucair WK, Lip GY, Ip J, Holcomb R, Akar JG, Halperin JL; IMPACT Investigators. Randomized trial of atrial arrhythmia monitoring to guide anticoagula- tion in patients with implanted defibrillator and cardiac resynchronization devices. Eur Heart J. 2015;36:1660 1668. doi: 10.1093/eurheartj/ehv115 348. Gladstone DJ, Spring M, Dorian P, Panzov V, Thorpe KE, Hall J, Vaid H, O Donnell M, Laupacis A, C t R, et al; EMBRACE Investigators and Coordinators. Atrial fibrillation in patients with cryptogenic stroke. N Engl J Med. 2014;370:2467 2477. doi: 10.1056/NEJMoa1311376 349. Higgins P, Dawson J, MacFarlane PW, McArthur K, Langhorne P, Lees KR. Predictive value of newly detected atrial fibrillation paroxysms in patients with acute ischemic stroke, for atrial fibrillation after 90 days. 350. Bath PM, Woodhouse LJ, Appleton JP, Beridze M, Christensen H, Dineen RA, Duley L, England TJ, Flaherty K, Havard D, et al; TARDIS Investigators. Antiplatelet therapy with aspirin, clopidogrel, and di- pyridamole versus clopidogrel alone or aspirin and dipyridamole in patients with acute cerebral ischaemia (TARDIS): a randomised, open-label, phase 3 superiority trial. Lancet. 2018;391:850 859. doi: 351. Meenan RT, Saha S, Chou R, Swarztrauber K, Krages KP, O Keefee-RosettiM,McDonaghM,ChanBK,HornbrookMC,HelfandM. Effectiveness and cost-effectiveness of echocardiography and carotid im- aging in the management of stroke. Evid Rep Technol Assess (Summ). 2002:1 10. Coutts SB.


Effectiveness and cost-effectiveness of echocardiography and carotid im- aging in the management of stroke. Evid Rep Technol Assess (Summ). 2002:1 10. Coutts SB. Acute ischaemic stroke or transient ischaemic attack and the need for inpatient echocardiography. Postgrad Med J. 2014;90:434 438. 353. Holmes M, Rathbone J, Littlewood C, Rawdin A, Stevenson M, Stevens J, Archer R, Evans P, Wang J. Routine echocardiography in the management of stroke and transient ischaemic attack: a systematic re- view and economic evaluation. Health Technol Assess. 2014;18:1 176. 354. McGrath ER, Paikin JS, Motlagh B, Salehian O, Kapral MK, O Donnell MJ. Transesophageal echocardiography in patients with cryp- togenic ischemic stroke: a systematic review. Am Heart J. 2014;168:706 355. Zhang L, Harrison JK, Goldstein LB. Echocardiography for the de- tection of cardiac sources of embolism in patients with stroke or tran- sient ischemic attack. J Stroke Cerebrovasc Dis. 2012;21:577 582. doi: 356. Schaer B, Sticherling C, Lyrer P, Osswald S. Cardiological diagnostic work-up in stroke patients: a comprehensive study of test results and therapeutic implications. Eur J Neurol. 2009;16:268 273. doi: 357. DouenA, Pageau N, Medic S. Usefulness of cardiovascular investigations in stroke management: clinical relevance and economic implications. 358. Wolber T, Maeder M, Atefy R, Bluzaite I, Blank R, Rickli H, Ammann P. Should routine echocardiography be performed in all patients with stroke? J Stroke Cerebrovasc Dis. 2007;16:1 7. doi: 359. Homma S, Thompson JL, Pullicino PM, Levin B, Freudenberger RS, Teerlink JR,Ammon SE, Graham S, Sacco RL, Mann DL, et al;WARCEF Investigators. Warfarin and aspirin in patients with heart failure and sinus rhythm. N Engl J Med. 2012;366:1859 1869. doi: 360. Massie BM, Collins JF, Ammon SE, Armstrong PW, Cleland JG, Ezekowitz M, Jafri SM, Krol WF, O Connor CM, Schulman KA, et al; for the WATCH Trial Investigators.


Massie BM, Collins JF, Ammon SE, Armstrong PW, Cleland JG, Ezekowitz M, Jafri SM, Krol WF, O Connor CM, Schulman KA, et al; for the WATCH Trial Investigators. Randomized trial of warfarin, aspirin, and clopidogrel in patients with chronic heart failure: the Warfarin and AntiplateletTherapyinChronicHeartFailure(WATCH)trial.Circulation. 361. Ahmad O, Ahmad KE, Dear KB, Harvey I, Hughes A, Lueck CJ. Echocardiography in the detection of cardioembolism in a stroke popula- tion. J Clin Neurosci. 2010;17:561 565. doi: 10.1016/j.jocn.2009.09.016 362. Secades S, Mart n M, Corros C, Rodr guez ML, Garc a-Campos A, de la Hera Galarza JM, Lambert JL. Diagnostic yield of echocardiography in stroke: should we improve patient selection? Neurologia. 2013;28:15 363. Kapral MK, Silver FL. Preventive health care, 1999 update, 2: echocar- diography for the detection of a cardiac source of embolus in patients with stroke: Canadian Task Force on Preventive Health Care. CMAJ. 1999;161:989 996. 364. Connors JM. Thrombophilia testing and venous thrombosis. N Engl J 365. Morris JG, Singh S, Fisher M. Testing for inherited thrombophilias in arterial stroke: can it cause more harm than good? Stroke. 2010;41:2985 366. Brown DL, Chervin RD, Hickenbottom SL, Langa KM, Morgenstern LB. Screening for obstructive sleep apnea in stroke patients: a cost-effectiveness analysis. Stroke. 2005;36:1291 1293. doi: 367. Pack AI, Pien GW. Update on sleep and its disorders. Annu Rev Med. 368. Medeiros CA, de Bruin VM, Andrade GM, Coutinho WM, de Castro-Silva C, de Bruin PF. Obstructive sleep apnea and biomarkers of inflammation in ischemic stroke. Acta Neurol Scand. 2012;126:17 22. 369. Camilo MR, Sander HH, Eckeli AL, Fernandes RM, Dos Santos-Pontelli TE, Leite JP, Pontes-Neto OM. SOS score: an opti- mized score to screen acute stroke patients for obstructive sleep apnea. Sleep Med. 2014;15:1021 1024. doi: 10.1016/j.sleep.2014.03.026 370.


SOS score: an opti- mized score to screen acute stroke patients for obstructive sleep apnea. Sleep Med. 2014;15:1021 1024. doi: 10.1016/j.sleep.2014.03.026 370. Stahl SM, Yaggi HK, Taylor S, Qin L, Ivan CS, Austin C, Ferguson J, Radulescu R, Tobias L, Sico J, et al. Infarct location and sleep apnea: evaluating the potential association in acute ischemic stroke. Sleep Med. P rez-Ronchel J, Dur n-Cantolla J, de la Torre G, Gonz lez Marcos JR, de la Pe a M, et al. Early treatment of obstructive apnoea and stroke out- come: a randomised controlled trial. Eur Respir J. 2011;37:1128 1136. 372. McEvoy RD, Antic NA, Heeley E, Luo Y, Ou Q, Zhang X, Mediano O, Chen R, Drager LF, Liu Z, et al; SAVE Investigators and Coordinators. CPAP for prevention of cardiovascular events in obstructive sleep apnea. N Engl J Med. 2016;375:919 931. doi: 10.1056/NEJMoa1606599 373. C t R, Zhang Y, Hart RG, McClure LA, Anderson DC, Talbert RL, Benavente OR. ASA failure: does the combination ASA/clopidogrel confer better long-term vascular protection? Neurology. 2014;82:382 374. Lee M, Saver JL, Hong KS, Rao NM, Wu YL, Ovbiagele B. Antiplatelet regimen for patients with breakthrough strokes while on aspirin: a sys- tematic review and meta-analysis. Stroke. 2017;48:2610 2613. doi: 375. John S, Katzan I. Recurrent stroke while on antiplatelet therapy. Neurol 376. Turan TN, Maidan L, Cotsonis G, Lynn MJ, Romano JG, Levine SR, ChimowitzMI;fortheWarfarin-AspirinSymptomaticIntracranialDisease Investigators. Failure of antithrombotic therapy and risk of stroke in patients with symptomatic intracranial stenosis. Stroke. 2009;40:505 377. Kasner SE, Lynn MJ, Chimowitz MI, Frankel MR, Howlett-Smith H, Hertzberg VS, Chaturvedi S, Levine SR, Stern BJ, Benesch CG, et al; Warfarin Aspirin Symptomatic Intracranial Disease (WASID) Trial Investigators. Warfarin vs aspirin for symptomatic intracranial stenosis: subgroup analyses from WASID. Neurology. 378.


Warfarin vs aspirin for symptomatic intracranial stenosis: subgroup analyses from WASID. Neurology. 378. Paciaroni M, Agnelli G, Falocci N, Caso V, Becattini C, Marcheselli S, Rueckert C, Pezzini A, Poli L, Padovani A, et al. Early recurrence and cerebral bleeding in patients with acute ischemic stroke and atrial fibril- lation: effect of anticoagulation and its timing: the RAF Study. Stroke. 379. Markus HS, Hayter E, Levi C, Feldman A, Venables G, Norris J; CADISS Trial Investigators. Antiplatelet treatment compared with anticoagulation treatment for cervical artery dissection (CADISS): a randomised trial. Lancet Neurol. 2015;14:361 367. doi: 10.1016/ 380. Larsson SC, King A, Madigan J, Levi C, Norris JW, Markus HS. Prognosis of carotid dissecting aneurysms: results from CADISS and a systematic review. Neurology. 2017;88:646 652. doi: 381. Ahlhelm F, Benz RM, Ulmer S, Lyrer P, Stippich C, Engelter S. Endovascular treatment of cervical artery dissection: ten case reports and review of the literature. Interv Neurol. 2013;1:143 150. doi: 382. Kim JT, Heo SH, Park MS, Chang J, Choi KH, Cho KH. Use of anti- thrombotics after hemorrhagic transformation in acute ischemic stroke. PLoS One. 2014;9:e89798. doi: 10.1371/journal.pone.0089798 383. England TJ, Bath PM, Sare GM, Geeganage C, Moulin T, O Neill D, Woimant F, Christensen H, De Deyn P, Leys D, et al; TAIST Investigators. Asymptomatic hemorrhagic transformation of infarction and its relation- ship with functional outcome and stroke subtype: assessment from the Tinzaparin in Acute Ischaemic Stroke Trial. Stroke. 2010;41:2834 2839. 384. Nissen SE, Stroes E, Dent-Acosta RE, Rosenson RS, Lehman SJ, Sattar N, Preiss D, Bruckert E, Ce ka R, Lepor N, et al; GAUSS-3 Investigators. Efficacy and tolerability of evolocumab vs ezetimibe in patients with muscle-related statin intolerance: the GAUSS-3 randomized clinical trial. JAMA. 2016;315:1580 1590. doi: 10.1001/jama.2016.3608 385.


Efficacy and tolerability of evolocumab vs ezetimibe in patients with muscle-related statin intolerance: the GAUSS-3 randomized clinical trial. JAMA. 2016;315:1580 1590. doi: 10.1001/jama.2016.3608 385. Moriarty PM, Thompson PD, Cannon CP, Guyton JR, Bergeron J, Zieve FJ, Bruckert E, Jacobson TA, Kopecky SL, Baccara-Dinet MT, et al; ODYSSEY ALTERNATIVE Investigators. Efficacy and safety of alirocumab vs ezetimibe in statin-intolerant patients, with a statin rechal- lenge arm: the ODYSSEY ALTERNATIVE randomized trial. J Clin 386. Lloyd-Jones DM, Morris PB, Ballantyne CM, Birtcher KK, Daly DD Jr, DePalma SM, Minissian MB, Orringer CE, Smith SC, Jr. 2016 ACC ex- pert consensus decision pathway on the role of non-statin therapies for LDL-cholesterol lowering in the management of atherosclerotic cardi- ovascular disease risk: a report of the American College of Cardiology Task Force on Clinical Expert Consensus Documents. J Am Coll Cardiol. 387. Sanossian N, Saver JL, Liebeskind DS, Kim D, Razinia T, Ovbiagele B. Achieving target cholesterol goals after stroke: is in-hos- pital statin initiation the key? Arch Neurol. 2006;63:1081 1083. doi: 388. Hong KS, Lee JS. Statins in acute ischemic stroke: a systematic review. J Stroke. 2015;17:282 301. doi: 10.5853/jos.2015.17.3.282 389. Kennedy J, Hill MD, Ryckborst KJ, Eliasziw M, Demchuk AM, Buchan AM; FASTER Investigators. Fast Assessment of Stroke and Transient Ischaemic Attack to Prevent Early Recurrence (FASTER): a randomised controlled pilot trial. Lancet Neurol. 2007;6:961 969. doi: 390. Yoshimura S, Uchida K, Daimon T, Takashima R, Kimura K, Morimoto T; on behalf of the ASSORT Trial Investigator. Randomized controlled trial of early versus delayed statin therapy in patients with acute ischemic stroke: ASSORT Trial (Administration of Statin on Acute Ischemic Stroke Patient). Stroke. 2017;48:3057 3063. doi: 391. Rigotti NA, Clair C, Munafo MR, Stead LF. Interventions for smok- ing cessation in hospitalised patients. Cochrane Database Syst Rev. 2012:CD001837. 392.


Interventions for smok- ing cessation in hospitalised patients. Cochrane Database Syst Rev. 2012:CD001837. 392. Lee MJ, Park E, Kim HC, Lee HS, Cha MJ, Kim YD, Heo JH, Nam HS. Timely interventions can increase smoking cessation rate in men with ischemic stroke. J Korean Acad Nurs. 2016;46:610 617. doi: 393. Eisenberg MJ, Windle SB, Roy N, Old W, Grondin FR, Bata I, Iskander A, Lauzon C, Srivastava N, Clarke A, et al; EVITA Investigators. Varenicline for smoking cessation in hospitalized patients with acute coronary syndrome. Circulation. 2016;133:21 30. doi: 394. Schwartz J, Dreyer RP, Murugiah K, Ranasinghe I. Contemporary pre- hospital emergency medical services response times for suspected stroke in the United States. Prehosp Emerg Care. 2016;20:560 565. doi: 395. Boden-Albala B, Stillman J, Roberts ET, Quarles LW, Glymour MM, Chong J, Moats H, Torrico V, Parides MC. Comparison of acute stroke preparedness strategies to decrease emergency de- partment arrival time in a multiethnic cohort: the Stroke Warning Information and Faster Treatment Study. Stroke. 2015;46:1806 1812. 396. Morgenstern LB, Gonzales NR, Maddox KE, Brown DL, Karim AP, Espinosa N, Moy LA, Pary JK, Grotta JC, Lisabeth LD, et al.A random- ized, controlled trial to teach middle school children to recognize stroke and call 911: the Kids Identifying and Defeating Stroke project. Stroke. 397. Kidwell CS, Starkman S, Eckstein M, Weems K, Saver JL. Identifying stroke in the field: prospective validation of the Los Angeles Prehospital 398. Bray JE, Martin J, Cooper G, Barger B, Bernard S, Bladin C. Paramedic identification of stroke: community validation of the Melbourne Ambulance Stroke Screen. Cerebrovasc Dis. 2005;20:28 33. doi: 399. Studnek JR,AsimosA, Dodds J, Swanson D.Assessing the validity of the CincinnatiPrehospitalStrokeScaleandtheMedicPrehospitalAssessment for Code Stroke in an urban emergency medical services agency. Prehosp Emerg Care. 2013;17:348 353. doi: 10.3109/10903127.2013.773113 400.


Studnek JR,AsimosA, Dodds J, Swanson D.Assessing the validity of the CincinnatiPrehospitalStrokeScaleandtheMedicPrehospitalAssessment for Code Stroke in an urban emergency medical services agency. Prehosp Emerg Care. 2013;17:348 353. doi: 10.3109/10903127.2013.773113 400. Chenkin J, Gladstone DJ, Verbeek PR, Lindsay P, Fang J, Black SE, Morrison L. Predictive value of the Ontario prehospital stroke screening tool for the identification of patients with acute stroke. Prehosp Emerg 401. Asimos AW, Ward S, Brice JH, Rosamond WD, Goldstein LB, Studnek J. Out-of-hospital stroke screen accuracy in a state with an emergency med- ical services protocol for routing patients to acute stroke centers. Ann 402. Pickham D, Valdez A, Demeestere J, Lemmens R, Diaz L, Hopper S, de la Cuesta K, Rackover F, Miller K, Lansberg MG. Prognostic value of BEFAST vs. FAST to identify stroke in a prehospital setting. Prehosp Emerg Care. 2019;23:195 200. doi: 10.1080/10903127.2018.1490837 403. van Wijngaarden JD, Dirks M, Niessen LW, Huijsman R, Dippel DW. Do centres with well-developed protocols, training and infrastructure have higher rates of thrombolysis for acute ischaemic stroke? QJM. 404. Jeng JS, Tang SC, Deng IC, Tsai LK,Yeh SJ,Yip PK. Stroke center char- acteristics which influence the administration of thrombolytic therapy for acute ischemic stroke: a national survey of stroke centers in Taiwan. J Neurol Sci. 2009;281:24 27. doi: 10.1016/j.jns.2009.03.004 405. Douglas VC, Tong DC, Gillum LA, Zhao S, Brass LM, Dostal J, Johnston SC. Do the Brain Attack Coalition s criteria for stroke centers improve care for ischemic stroke? Neurology. 2005;64:422 427. doi: 406. Asimos AW, Norton HJ, Price MF, Cheek WM. Therapeutic yield and outcomes of a community teaching hospital code stroke protocol. Acad Emerg Med. 2004;11:361 370. doi: 10.1197/j.aem.2003.12.016 407. Sauser K, Levine DA, Nickles AV, Reeves MJ.


2004;11:361 370. doi: 10.1197/j.aem.2003.12.016 407. Sauser K, Levine DA, Nickles AV, Reeves MJ. Hospital variation in thrombolysis times among patients with acute ischemic stroke: the con- tributions of door-to-imaging time and imaging-to-needle time. JAMA Dodick DW, Ward MP, Richemont PC, Brazdys K, et al; for the STRokE DOC AZ TIME Investigators. Stroke team remote evaluation using a dig- italobservationcamerainArizona:theinitialMayoClinicexperiencetrial. 409. Meyer BC, Raman R, Hemmen T, Obler R, Zivin JA, Rao R, Thomas RG, Lyden PD. Efficacy of site-independent telemedicine in the STRokE DOC trial: a randomised, blinded, prospective study. Lancet Neurol. 410. Rai AT, Smith MS, Boo S, Tarabishy AR, Hobbs GR, Carpenter JS. The pit-crew model for improving door-to-needle times in endovascular stroke therapy: a Six-Sigma project. J Neurointerv Surg. 2016;8:447 411. Muir KW, Ford GA, Messow CM, Ford I, Murray A, Clifton A, Brown MM, Madigan J, Lenthall R, Robertson F, et al; PISTE Investigators. Endovascular therapy for acute ischaemic stroke: the Pragmatic Ischaemic Stroke Thrombectomy Evaluation (PISTE) ran- domised, controlled trial. J Neurol Neurosurg Psychiatry. 2017;88:38 412. Mocco J, Zaidat OO, von Kummer R, Yoo AJ, Gupta R, Lopes D, Frei D, Shownkeen H, Budzik R, Ajani ZA, et al; THERAPY Trial Investigators. Aspiration thrombectomy after intravenous alteplase versus intravenous alteplase alone. Stroke. 2016;47:2331 2338. doi: 413. Broderick JP, Palesch YY, Demchuk AM, Yeatts SD, Khatri P, Hill MD, Jauch EC, Jovin TG, Yan B, Silver FL, et al; Interventional Management of Stroke (IMS) III Investigators. Endovascular therapy after intravenous t-PA versus t-PA alone for stroke. N Engl J Med. 2013;368:893 903. doi: 414. Ciccone A, Valvassori L, Nichelatti M, Sgoifo A, Ponzio M, Sterzi R, Boccardi E; SYNTHESIS Expansion Investigators. Endovascular treat- ment for acute ischemic stroke. N Engl J Med. 2013;368:904 913. doi: Powers et al 2019 Guidelines for Management of AIS e415 415.


2013;368:904 913. doi: Powers et al 2019 Guidelines for Management of AIS e415 415. Kidwell CS, Jahan R, Gornbein J, Alger JR, Nenov V, Ajani Z, Feng L, Meyer BC, Olson S, Schwamm LH, et al; MR RESCUE Investigators. A trial of imaging selection and endovascular treatment for ischemic stroke. N Engl J Med. 2013;368:914 923. doi: 10.1056/NEJMoa1212793 416. Nogueira RG, Lutsep HL, Gupta R, Jovin TG, Albers GW, Walker GA, Liebeskind DS, Smith WS; TREVO 2 Trialists. Trevo versus Merci retrievers for thrombectomy revascularisation of large vessel occlu- sions in acute ischaemic stroke (TREVO 2): a randomised trial. Lancet. 417. Saver JL, Jahan R, Levy EI, Jovin TG, Baxter B, Nogueira RG, Clark W, Budzik R, Zaidat OO; SWIFT Trialists. Solitaire flow restoration de- vice versus the Merci retriever in patients with acute ischaemic stroke (SWIFT): a randomised, parallel-group, non-inferiority trial. Lancet. 418. Ogawa A, Mori E, Minematsu K, Taki W, Takahashi A, Nemoto S, Miyamoto S, Sasaki M, Inoue T; for the MELT Japan Study Group. Randomized trial of intraarterial infusion of urokinase within 6 hours of middle cerebral artery stroke: the Middle Cerebral Artery Embolism Local Fibrinolytic Intervention Trial (MELT) Japan. Stroke. 419. Furlan A, Higashida R, Wechsler L, Gent M, Rowley H, Kase C, Pessin M, Ahuja A, Callahan F, Clark WM, et al. Intra-arterial prouro- kinase for acute ischemic stroke: the PROACT II study: a randomized controlled trial: Prolyse in Acute Cerebral Thromboembolism. JAMA. 420. Brazzelli M, Sandercock PA, Chappell FM, Celani MG, Righetti E, Arestis N,Wardlaw JM, Deeks JJ. Magnetic resonance imaging versus com- puted tomography for detection of acute vascular lesions in patients present- ing with stroke symptoms. Cochrane Database Syst Rev. 2009:CD007424. 421. Wardlaw JM, Carpenter T, Sakka E, Mair G, Cohen G, Shuler K, Palmer JM, Innes K, Sandercock PA.


Wardlaw JM, Carpenter T, Sakka E, Mair G, Cohen G, Shuler K, Palmer JM, Innes K, Sandercock PA. Imaging perfusion deficits, arterial patency and thrombolysis safety and efficacy in acute ischaemic stroke An observational study of the effect of advanced imaging methods in the Third International Stroke Trial (IST-3), a randomised controlled trial. In: Efficacy and Mechanism Evaluation, No. 1.1. Southampton, UK: NIHR Journals Library; 2014. 422. Davis SM, Donnan GA, Parsons MW, Levi C, Butcher KS, Peeters A, Barber PA, Bladin C, De Silva DA, Byrnes G, et al; EPITHET Investigators. Effects of alteplase beyond 3 h after stroke in the Echoplanar Imaging Thrombolytic Evaluation Trial (EPITHET): a pla- cebo-controlled randomised trial. Lancet Neurol. 2008;7:299 309. doi: 423. Furlan AJ, Eyding D, Albers GW, Al-Rawi Y, Lees KR, Rowley HA, Sachara C, Soehngen M, Warach S, Hacke W; DEDAS Investigators. Dose Escalation of Desmoteplase for Acute Ischemic Stroke (DEDAS): evidence of safety and efficacy 3 to 9 hours after stroke onset. Stroke. 424. Clark WM, Albers GW, Madden KP, Hamilton S. The rtPA (alteplase) 0- to 6-hour acute stroke trial, part A (A0276g): results of a double-blind, placebo-controlled, multicenter study: Thrombolytic Therapy in Acute Ischemic Stroke Study Investigators. Stroke. 2000;31:811 816. doi: 425. Clark WM, Wissman S, Albers GW, Jhamandas JH, Madden KP, Hamilton S. Recombinant tissue-type plasminogen activator (alteplase) for ischemic stroke 3 to 5 hours after symptom onset: the ATLANTIS Study: a randomized controlled trial: Alteplase Thrombolysis for Acute Noninterventional Therapy in Ischemic Stroke. JAMA. 1999;282:2019 426. Hacke W, Kaste M, Fieschi C, von Kummer R, Davalos A, Meier D, LarrueV, Bluhmki E, Davis S, Donnan G, et al. Randomised double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS II): Second European- Australasian Acute Stroke Study Investigators. Lancet. 1998;352:1245 427.


Randomised double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS II): Second European- Australasian Acute Stroke Study Investigators. Lancet. 1998;352:1245 427. Hacke W, Kaste M, Fieschi C, Toni D, Lesaffre E, von Kummer R, Boysen G, Bluhmki E, H xter G, Mahagne MH. Intravenous thromboly- sis with recombinant tissue plasminogen activator for acute hemispheric stroke: the European Cooperative Acute Stroke Study (ECASS). JAMA. 1995;274:1017 1025. 428. Seet RC, Rabinstein AA. Symptomatic intracranial hemorrhage fol- lowing intravenous thrombolysis for acute ischemic stroke: a critical review of case definitions. Cerebrovasc Dis. 2012;34:106 114. doi: 429. Ali K, Warusevitane A, Lally F, Sim J, Sills S, Pountain S, Nevatte T, AllenM,RoffeC.TheStrokeOxygenPilotStudy:arandomizedcontrolled trial of the effects of routine oxygen supplementation early after acute stroke: effect on key outcomes at six months. PLoS One. 2014;8:e59274. 430. Singhal A, Partners SPOTRIAS Investigators. A phase IIB clinical trial of normobaric oxygen therapy (NBO) in acute ischemic stroke (AIS) (S02.001). Neurology. 2013;80(suppl):S02.001. 431. Roffe C, Ali K, Warusevitane A, Sills S, Pountain S, Allen M, Hodsoll J, Lally F, Jones P, Crome P. The SOS pilot study: a RCT of rou- tine oxygen supplementation early after acute stroke: effect on recovery of neurological function at one week. PLoS One. 2011;6:e19113. doi: 432. Roffe C, Sills S, Pountain SJ, Allen M. A randomized controlled trial of the effect of fixed-dose routine nocturnal oxygen supplementation on ox- ygen saturation in patients with acute stroke. J Stroke Cerebrovasc Dis. 433. Singhal AB, Benner T, Roccatagliata L, Koroshetz WJ, Schaefer PW, Lo EH, Buonanno FS, Gonzalez RG, Sorensen AG. A pilot study of nor- mobaric oxygen therapy in acute ischemic stroke. Stroke. 2005;36:797 434. R nning OM, Guldvog B. Should stroke victims routinely receive supplemental oxygen? A quasi-randomized controlled trial. Stroke. 435. AdelmanEE,ScottPA,SkolarusLE,FoxAK,FrederiksenSM,MeurerWJ.


Should stroke victims routinely receive supplemental oxygen? A quasi-randomized controlled trial. Stroke. 435. AdelmanEE,ScottPA,SkolarusLE,FoxAK,FrederiksenSM,MeurerWJ. Protocol deviations before and after treatment with intravenous tissue plasminogen activator in community hospitals. J Stroke Cerebrovasc Dis. 436. Kodankandath TV, Shaji J, Kohn N, Arora R, Salamon E, Libman RB, Katz JM. Poor hypertension control and longer trans- port times are associated with worse outcome in drip-and-ship stroke patients. J Stroke Cerebrovasc Dis. 2016;25:1887 1890. doi: RawalPV,KapoorN,AlviM,SissonA,AlexandrovAW,etal.Safetyofpro- tocol violations in acute stroke tPA administration. J Stroke Cerebrovasc 438. Kellert L, Rocco A, Sykora M, Hacke W, Ringleb PA. Frequency of increased blood pressure levels during systemic thrombolysis and risk of intracerebral hemorrhage. Stroke. 2011;42:1702 1706. doi: 439. Karaszewski B, Thomas RG, Dennis MS, Wardlaw JM. Temporal profile of body temperature in acute ischemic stroke: relation to stroke severity 440. den Hertog HM, van derWorp HB, van Gemert HM,AlgraA, Kappelle LJ, van Gijn J, Koudstaal PJ, Dippel DW. An early rise in body temperature is related to unfavorable outcome after stroke: data from the PAIS study. J Neurol. 2011;258:302 307. doi: 10.1007/s00415-010-5756-4 441. Broessner G, Beer R, Lackner P, Helbok R, Fischer M, Pfausler B, Rhorer J, K ppers-Tiedt L, Schneider D, Schmutzhard E. Prophylactic, endovascularly based, long-term normothermia in ICU patients with severe cerebrovascular disease: bicenter prospective, randomized trial. 442. den Hertog HM, van der Worp HB, van Gemert HM, Algra A, Kappelle LJ, van Gijn J, Koudstaal PJ, Dippel DW; PAIS Investigators. The Paracetamol (Acetaminophen) In Stroke (PAIS) trial: a multicen- tre, randomised, placebo-controlled, phase III trial. Lancet Neurol. 443. Horn CM, Sun CH, Nogueira RG, Patel VN, Krishnan A, Glenn BA, Belagaje SR, Thomas TT,AndersonAM, Frankel MR, et al. Endovascular Reperfusion and Cooling in Cerebral Acute Ischemia (ReCCLAIM I). J Neurointerv Surg. 2014;6:91 95. doi: 10.1136/neurintsurg-2013-010656 444.


Endovascular Reperfusion and Cooling in Cerebral Acute Ischemia (ReCCLAIM I). J Neurointerv Surg. 2014;6:91 95. doi: 10.1136/neurintsurg-2013-010656 444. Su Y, Fan L, Zhang Y, Zhang Y, Ye H, Gao D, Chen W, Liu G. Improved neurological outcome with mild hypothermia in surviving patients with massive cerebral hemispheric infarction. Stroke. 2016;47:457 463. doi: hypothermia after recanalization in patients with acute ischemic stroke. 446. Ovesen C, Brizzi M, Pott FC, Thorsen-Meyer HC, Karlsson T, Ersson A, Christensen H, Norrlin A, Meden P, Krieger DW, et al. Feasibility of endovascular and surface cooling strategies in acute stroke. Acta Neurol 447. Li W, Lin L, Zhang M, Wu Y, Liu C, Li X, Huang S, Liang C, Wang Y, Chen J, et al. Safety and preliminary efficacy of early tirofiban treatment after alteplase in acute ischemic stroke patients. Stroke. 2016;47:2649 448. Wada T,Yasunaga H, Horiguchi H, Fushimi K, Matsubara T, Nakajima S, Yahagi N. Ozagrel for patients with noncardioembolic ischemic stroke: a propensity score-matched analysis. J Stroke Cerebrovasc Dis. 449. Mori E, Minematsu K, Nakagawara J, HasegawaY, Nagahiro S, OkadaY, Truelsen T, Lindsten A, Ogawa A,Yamaguchi T; on behalf of the DIAS-J Investigators. Safety and tolerability of desmoteplase within 3 to 9 hours after symptoms onset in Japanese patients with ischemic stroke. Stroke. 450. Multicenter Acute Stroke Trial Europe Study Group, Hommel M, Cornu C, Boutitie F, Boissel JP. Thrombolytic therapy with streptoki- nase in acute ischemic stroke. N Engl J Med. 1996;335:145 150. doi: 451. Multicentre Acute Stroke Trial Italy (MAST-I) Group. Randomised con- trolled trial of streptokinase, aspirin, and combination of both in treat- ment of acute ischaemic stroke. Lancet. 1995;346:1509 1514. 452. Coutinho JM, Liebeskind DS, Slater LA, Nogueira RG, Clark W, Davalos A, Bonafe A, Jahan R, Fischer U, Gralla J, et al.


Coutinho JM, Liebeskind DS, Slater LA, Nogueira RG, Clark W, Davalos A, Bonafe A, Jahan R, Fischer U, Gralla J, et al. Combined in- travenous thrombolysis and thrombectomy vs thrombectomy alone for acute ischemic stroke: a pooled analysis of the SWIFT and STAR studies. JAMA Neurol. 2017;74:268 274. doi: 10.1001/jamaneurol.2016.5374 453. Grech R, Pullicino R, Thornton J, Downer J. An efficacy and safety com- parison between different stentriever designs in acute ischaemic stroke: a systematic review and meta-analysis. Clin Radiol. 2016;71:48 57. doi: 454. Rodrigues FB, Neves JB, Caldeira D, Ferro JM, Ferreira JJ, Costa J. Endovascular treatment versus medical care alone for ischaemic stroke: systematic review and meta-analysis. BMJ. 2016;353:i1754. doi: 455. Touma L, Filion KB, Sterling LH, Atallah R, Windle SB, Eisenberg MJ. Stent retrievers for the treatment of acute ischemic stroke: a systematic review and meta-analysis of randomized clinical trials. JAMA Neurol. 456. Badhiwala JH, Nassiri F,Alhazzani W, Selim MH, Farrokhyar F, Spears J, Kulkarni AV, Singh S, Alqahtani A, Rochwerg B, et al. Endovascular thrombectomy for acute ischemic stroke: a meta-analysis. JAMA. 457. Chen CJ, Ding D, Starke RM, Mehndiratta P, Crowley RW, Liu KC, Southerland AM, Worrall BB. Endovascular vs medical man- agement of acute ischemic stroke. Neurology. 2015;85:1980 1990. doi: 458. Elgendy IY, Kumbhani DJ, Mahmoud A, Bhatt DL, Bavry AA. Mechanical Thrombectomy for acute ischemic stroke: a meta-analysis of randomized trials. J Am Coll Cardiol. 2015;66:2498 2505. doi: 459. Fargen KM, Neal D, Fiorella DJ, Turk AS, Froehler M, Mocco J. A meta-analysis of prospective randomized controlled trials evaluating endovascular therapies for acute ischemic stroke. J Neurointerv Surg. 460. Kumar G, Shahripour RB, Alexandrov AV. Recanalization of acute bas- ilar artery occlusion improves outcomes: a meta-analysis. J Neurointerv 461. Marmagkiolis K, Hakeem A, Cilingiroglu M, Gundogdu B, Iliescu C, Tsitlakidou D, Katramados A.


Marmagkiolis K, Hakeem A, Cilingiroglu M, Gundogdu B, Iliescu C, Tsitlakidou D, Katramados A. Safety and efficacy of stent retrievers for the management of acute ischemic stroke: comprehensive review and meta-analysis. JACC Cardiovasc Interv. 2015;8:1758 1765. doi: 462. Yarbrough CK, Ong CJ, Beyer AB, Lipsey K, Derdeyn CP. Endovascular thrombectomy for anterior circulation stroke: systematic review and meta-analysis. Stroke. 2015;46:3177 3183. doi: 10.1161/STROKEAHA. 463. Almekhlafi MA, Menon BK, Freiheit EA, Demchuk AM, Goyal M. A meta-analysis of observational intra-arterial stroke therapy studies using the Merci device, Penumbra system, and retrievable stents. AJNR Am J 464. Fields JD, Khatri P, Nesbit GM, Liu KC, Barnwell SL, Lutsep HL, Clark WM, Lansberg MG. Meta-analysis of randomized intra-arterial thrombolytic trials for the treatment of acute stroke due to middle ce- rebral artery occlusion. J Neurointerv Surg. 2011;3:151 155. doi: 465. L whagen Hend n P, Rentzos A, Karlsson JE, Rosengren L, Leiram B, Sundeman H, Dunker D, Schnabel K, Wikholm G, Hellstr m M, et al. General anesthesia versus conscious sedation for endovascular treatment of acute ischemic stroke: the AnStroke trial (Anesthesia During Stroke). 466. BrinjikjiW,MuradMH,RabinsteinAA,CloftHJ,LanzinoG,KallmesDF. Conscious sedation versus general anesthesia during endovascular acute ischemic stroke treatment: a systematic review and meta-analysis. AJNR Am J Neuroradiol. 2015;36:525 529. doi: 10.3174/ajnr.A4159 467. Wada T, Yasunaga H, Horiguchi H, Matsubara T, Fushimi K, Nakajima S, Yahagi N. Outcomes of argatroban treatment in patients with atherothrombotic stroke: observational nationwide study in Japan. 468. Sandercock PA, Counsell C, Kamal AK. Anticoagulants for acute isch- aemic stroke. Cochrane Database Syst Rev. 2008:CD000024. 469. Wang Q, Chen C, Chen XY, Han JH, Soo Y, Leung TW, Mok V, Wong KS. Low-molecular-weight heparin and early neurologic deteri- oration in acute stroke caused by large artery occlusive disease. Arch 470.


Low-molecular-weight heparin and early neurologic deteri- oration in acute stroke caused by large artery occlusive disease. Arch 470. Wang QS, Chen C, Chen XY, Han JH, SooY, LeungTW, MokV,Wong KS. Low-molecular-weight heparin versus aspirin for acute ischemic stroke with large artery occlusive disease: subgroup analyses from the Fraxiparin in Stroke Study for the treatment of ischemic stroke (FISS-tris) study. 471. Abdul-Rahim AH, Fulton RL, Frank B, Tatlisumak T, Paciaroni M, Caso V, Diener HC, Lees KR; VISTA Collaborators. Association of improved outcome in acute ischaemic stroke patients with atrial fibrilla- tion who receive early antithrombotic therapy: analysis from VISTA. Eur J Neurol. 2015;22:1048 1055. doi: 10.1111/ene.12577 472. Jensen J, Salottolo K, Frei D, Loy D, McCarthy K, Wagner J, Whaley M, Bellon R, Bar-Or D. Comprehensive analysis of intra-arterial treatment for acute ischemic stroke due to cervical artery dissection. J Neurointerv 473. Deleted in proof. 474. Seedat J, Penn C. Implementing oral care to reduce aspiration pneu- monia amongst patients with dysphagia in a South African setting. S Afr J Commun Disord. 2016;63. doi: 10.4102/sajcd.v63i1.102 475. Geeganage CM, Sprigg N, Bath MW, Bath PM. Balance of symptomatic pulmonary embolism and symptomatic intracerebral hemorrhage with low-doseanticoagulationinrecentischemicstroke:asystematicreviewand meta-analysis of randomized controlled trials. J Stroke Cerebrovasc Dis. 476. Qaseem A, Chou R, Humphrey LL, Starkey M, Shekelle P; Clinical Guidelines Committee of the American College of Physicians. Venous thromboembolism prophylaxis in hospitalized patients: a clinical prac- tice guideline from the American College of Physicians. Ann Intern Med. 477. Wang SB, Wang YY, Zhang QE, Wu SL, Ng CH, Ungvari GS, Chen L, Wang CX, Jia FJ, XiangYT. Cognitive behavioral therapy for post-stroke depression: a meta-analysis. J Affect Disord. 2018;235:589 596. doi: 478. Qin B, Chen H, Gao W, Zhao LB, Zhao MJ, Qin HX, Chen W, Chen L, Yang MX.


Qin B, Chen H, Gao W, Zhao LB, Zhao MJ, Qin HX, Chen W, Chen L, Yang MX. Efficacy, acceptability, and tolerability of antide- pressant treatments for patients with post-stroke depression: a network meta-analysis. Braz J Med Biol Res. 2018;51:e7218. doi: 10.1590/ 479. Cui M, Huang CY, Wang F. Efficacy and safety of citalopram for the treat- ment of poststroke depression: a meta-analysis. J Stroke Cerebrovasc Dis. 480. Deng L, Qiu S, Yang Y, Wang L, Li Y, Lin J, Wei Q, Yang L, Wang D, Liu M. Efficacy and tolerability of pharmacotherapy for post-stroke de- pression: a network meta-analysis. Oncotarget. 2018;9:23718 23728. 481. Sun Y, Liang Y, Jiao Y, Lin J, Qu H, Xu J, Zhao C. Comparative efficacy and acceptability of antidepressant treatment in poststroke depression: a multiple-treatments meta-analysis. BMJ Open. 2017;7:e016499. doi: 482. Deng L, Sun X, Qiu S, Xiong Y, Li Y, Wang L, Wei Q, Wang D, Liu M. Interventions for management of post-stroke depression: a bayesian network meta-analysis of 23 randomized controlled trials. Sci Rep. 483. Shen X, Liu M, Cheng Y, Jia C, Pan X, Gou Q, Liu X, Cao H, Zhang L. Repetitive transcranial magnetic stimulation for the treatment of post- stroke depression: a systematic review and meta-analysis of random- ized controlled clinical trials. J Affect Disord. 2017;211:65 74. doi: 484. Xu XM, Zou DZ, Shen LY, Liu Y, Zhou XY, Pu JC, Dong MX, Wei YD. Efficacy and feasibility of antidepressant treatment in patients with post-stroke depression. Medicine (Baltimore). 2016;95:e5349. doi: Powers et al 2019 Guidelines for Management of AIS e417 485. Tan S, Huang X, Ding L, Hong H. Efficacy and safety of citalopram in treating post-stroke depression: a meta-analysis. Eur Neurol. 486. Hackett ML, Anderson CS, House A, Xia J. Interventions for treating depression after stroke.


Hackett ML, Anderson CS, House A, Xia J. Interventions for treating depression after stroke. Cochrane Database Syst Rev. 2008:CD003437. 487. Herisson F, Godard S, Volteau C, Le Blanc E, Guillon B, Gaudron M; SEVEL Study Group. Early Sitting in Ischemic Stroke Patients (SEVEL): a randomized controlled trial. PLoS One. 2016;11:e0149466. doi: 488. Morreale M, Marchione P, Pili A, Lauta A, Castiglia SF, Spallone A, Pierelli F, Giacomini P. Early versus delayed rehabilitation treatment in hemiplegic patients with ischemic stroke: proprioceptive or cognitive approach? Eur J Phys Rehabil Med. 2016;52:81 89. 489. Meenan RT, Saha S, Chou R, Swarztrauber K, Pyle Krages K, O Keeffe-RosettiMC,McDonaghM,ChanBK,HornbrookMC,HelfandM. Cost-effectiveness of echocardiography to identify intracardiac thrombus among patients with first stroke or transient ischemic attack. Med Decis 490. McNamara RL, Lima JA, Whelton PK, Powe NR. Echocardiographic identification of cardiovascular sources of emboli to guide clinical management of stroke: a cost-effectiveness analysis. Ann Intern Med. 491. Shariat A, Yaghoubi E, Farazdaghi M, Aghasadeghi K, Borhani Haghighi A. Comparison of medical treatments in cryptogenic stroke patients with patent foramen ovale: a randomized clinical trial. J Res Med Sci. 2013;18:94 98. 492. Homma S, Sacco RL, Di Tullio MR, Sciacca RR, Mohr JP; for the PFO in Cryptogenic Stroke Study (PICSS) Investigators. Effect of medical treatment in stroke patients with patent foramen ovale: Patent Foramen Ovale in Cryptogenic Stroke Study. Circulation. 2002;105:2625 2631. 493. Ma Y, Li D, Bai F, Qin F, Li J, Li Y, Liu N, Xie H, Zhou S, Liu Q. Patent foramen ovale closure or medical therapy for secondary pre- vention of cryptogenic stroke: an update meta-analysis of random- ized controlled trials. Medicine (Baltimore). 2018;97:e11965. doi: 494.


Patent foramen ovale closure or medical therapy for secondary pre- vention of cryptogenic stroke: an update meta-analysis of random- ized controlled trials. Medicine (Baltimore). 2018;97:e11965. doi: 494. Schulze V, Lin Y, Karathanos A, Brockmeyer M, Zeus T, Polzin A, Perings S, Kelm M, Wolff G. Patent foramen ovale closure or medical therapy for cryptogenic ischemic stroke: an updated meta-analysis of randomized controlled trials. Clin Res Cardiol. 2018;107:745 755. doi: 495. Fiorelli EM, Carandini T, Gagliardi D, Bozzano V, Bonzi M, Tobaldini E, Comi GP, Scarpini EA, Montano N, Solbiati M. Secondary prevention of cryptogenic stroke in patients with patent foramen ovale: a systematic review and meta-analysis. Intern Emerg Med. 2018;13:1287 1303. doi: 496. Xu HB, Zhang H, Qin Y, Xue F, Xiong G, Yang L, Bai H, Wu J. Patent foramen ovale closure versus medical therapy for cryptogenic stroke: An updated meta-analysis. J Neurol Sci. 2018;390:139 149. doi: 497. Tsivgoulis G, Katsanos AH, Mavridis D, Frogoudaki A, Vrettou AR, Ikonomidis I, Parissis J, Deftereos S, Karapanayiotides T, Palaiodimou L, et al. Percutaneous patent foramen ovale closure for secondary stroke prevention: network meta-analysis. Neurology. 2018;91:e8 e18. doi: 498. Ahmad Y, Howard JP, Arnold A, Shin MS, Cook C, Petraco R, Demir O, Williams L, Iglesias JF, Sutaria N, et al. Patent foramen ovale closure vs. medical therapy for cryptogenic stroke: a meta-analysis of ran- domized controlled trials. Eur Heart J. 2018;39:1638 1649. doi: 499. Riaz H, Khan MS, Schenone AL, Waheed AA, Khan AR, Krasuski RA. Transcatheter closure of patent foramen ovale following cryptogenic stroke: an updated meta-analysis of randomized controlled trials. Am Heart J. 2018;199:44 50. doi: 10.1016/j.ahj.2018.01.008 500. Shah R, Nayyar M, Jovin IS, RashidA, Bondy BR, Fan TM, Flaherty MP, Rao SV.


Shah R, Nayyar M, Jovin IS, RashidA, Bondy BR, Fan TM, Flaherty MP, Rao SV. Device closure versus medical therapy alone for patent foramen ovale in patients with cryptogenic stroke: a systematic review and meta- analysis. Ann Intern Med. 2018;168:335 342. doi: 10.7326/M17-2679 501. De Rosa S, Sievert H, Sabatino J, Polimeni A, Sorrentino S, Indolfi C. Percutaneous closure versus medical treatment in stroke patients with patent foramen ovale: a systematic review and meta-analysis. Ann Intern 502. Zhang XL, Kang LN, Wang L, Xu B. Percutaneous closure versus medical therapy for stroke with patent foramen ovale: a systematic re- view and meta-analysis. BMC Cardiovasc Disord. 2018;18:45. doi: 503. Palaiodimos L, Kokkinidis DG, Faillace RT, Foley TR, Dangas GD, Price MJ, Mastoris I. Percutaneous closure of patent foramen ovale vs. medical treatment for patients with history of cryptogenic stroke: a systematic review and meta-analysis of randomized controlled trials. Cardiovasc Revasc Med. 2018;19(pt B):852 858. doi: 504. Ando T, Holmes AA, Pahuja M, Javed A, Briasoulis A, Telila T, Takagi H, Schreiber T, Afonso L, Grines CL, et al. Meta-analysis com- paring patent foramen ovale closure versus medical therapy to prevent recurrent cryptogenic stroke. Am J Cardiol. 2018;121:649 655. doi: 505. Lattanzi S, Brigo F, Cagnetti C, Di Napoli M, Silvestrini M. Patent fo- ramen ovale and cryptogenic stroke or transient ischemic attack: to close or not to close? A systematic review and meta-analysis. Cerebrovasc Dis. 506. Higgins JP, Altman DG, G tzsche PC, J ni P, Moher D, Oxman AD, SavovicJ,SchulzKF,WeeksL,SterneJA;CochraneBiasMethodsGroup; Cochrane Statistical Methods Group. The Cochrane Collaboration s tool for assessing risk of bias in randomised trials. BMJ. 2011;343:d5928. 507. Johansson E, Cuadrado-Godia E, Hayden D, Bjellerup J, OisA, Roquer J, Wester P, Kelly PJ. Recurrent stroke in symptomatic carotid stenosis awaiting revascularization: a pooled analysis. Neurology. 2016;86:498 508.


Recurrent stroke in symptomatic carotid stenosis awaiting revascularization: a pooled analysis. Neurology. 2016;86:498 508. Bazan HA, Zea N, Jennings B, Smith TA, Vidal G, Sternbergh WC 3rd. Urgent carotid intervention is safe after thrombolysis for minor to mod- erate acute ischemic stroke. J Vasc Surg. 2015;62:1529 1538. doi: 509. Chisci E, Pigozzi C, Troisi N, Tramacere L, Zaccara G, Cincotta M, ErcoliniL,MichelagnoliS.Thirty-dayneurologicimprovementassociated withearlyversusdelayedcarotidendarterectomyinsymptomaticpatients. Ann Vasc Surg. 2015;29:435 442. doi: 10.1016/j.avsg.2014.08.028 510. Devlin TG, Phade SV, Hutson RK, Fugate MW, Major GR 2nd, Albers GW, Sirelkhatim AA, Sapkota BL, Quartfordt SD, Baxter BW. Computed tomography perfusion imaging in the selection of acute stroke patients to undergo emergent carotid endarterectomy. Ann Vasc Surg. 511. Steglich-Arnholm H, Holtmannsp tter M, Kondziella D, Wagner A, StavngaardT,CronqvistME,HansenK,H jgaardJ,TaudorfS,KriegerDW. Thrombectomy assisted by carotid stenting in acute ischemic stroke management: benefits and harms. J Neurol. 2015;262:2668 2675. doi: 512. Ferrero E, Ferri M, Viazzo A, Labate C, Berardi G, Pecchio A, Piazza S, Ripepi M, Nessi F. A retrospective study on early carotid endarterectomy within 48 hours after transient ischemic attack and stroke in evolution. Ann Vasc Surg. 2014;28:227 238. doi: 10.1016/j.avsg.2013.02.015 513. Liu L, Wong KS, Leng X, Pu Y, Wang Y, Jing J, Zou X, Pan Y, Wang A, Meng X, et al; CHANCE Investigators. Dual antiplatelet therapy in stroke and ICAS: subgroup analysis of CHANCE. Neurology. 2015;85:1154 514. Jung JM, Kang DW, Yu KH, Koo JS, Lee JH, Park JM, Hong KS, Cho YJ, Kim JS, Kwon SU; TOSS-2 Investigators. Predictors of recur- rent stroke in patients with symptomatic intracranial arterial stenosis. 515. Coutts SB, Wein TH, Lindsay MP, Buck B, Cote R, Ellis P, Foley N, Hill MD, Jaspers S, Jin AY, et al; Heart, and Stroke Foundation Canada Canadian Stroke Best Practices Advisory Committee.


Coutts SB, Wein TH, Lindsay MP, Buck B, Cote R, Ellis P, Foley N, Hill MD, Jaspers S, Jin AY, et al; Heart, and Stroke Foundation Canada Canadian Stroke Best Practices Advisory Committee. Canadian stroke best practice recommendations: secondary prevention of stroke guide- lines, update 2014. Int J Stroke. 2015;10:282 291. doi: 10.1111/ijs.12439 516. Lanza G, Ricci S, Setacci C, Castelli P, Novalil C, Pratesi C, Speziale F, Cremonesi A, Morlacchi E, Lanza J, et al. An update on Italian Stroke Organization guidelines on carotid endarterectomy and stenting. Int J 517. Kakisis JD, Avgerinos ED, Antonopoulos CN, Giannakopoulos TG, Moulakakis K, Liapis CD. The European Society for Vascular Surgery guidelines for carotid intervention: an updated independent assessment and literature review. Eur J Vasc Endovasc Surg. 2012;44:238 243. 518. Paraskevas KI, Mikhailidis DP, Veith FJ. Comparison of the five 2011 guidelines for the treatment of carotid stenosis. J Vasc Surg. 2012;55:1504 1508. 519. Brott TG, Halperin JL, Abbara S, Bacharach JM, Barr JD, Bush RL, Cates CU, Creager MA, Fowler SB, Friday G, et al. 2011 ASA/ACCF/ AHA/AANN/AANS/ACR/ASNR/CNS/SAIP/SCAI/SIR/SNIS/SVM/SVS guideline on the management of patients with extracranial carotid and verte- bral artery disease: executive summary: a report of theAmerican College of Cardiology Foundation/American HeartAssociation Task Force on Practice Guidelines, and the American Stroke Association, American Association of Neuroscience Nurses, American Association of Neurological Surgeons, American College of Radiology, American Society of Neuroradiology, Congress of Neurological Surgeons, Society of Atherosclerosis Imaging and Prevention, Society for CardiovascularAngiography and Interventions, Society of Interventional Radiology, Society of NeuroInterventional Surgery, Society for Vascular Medicine, and Society for Vascular Surgery [published correction appears in Circulation. 2011;124:e145]. Circulation. 520. Ricotta JJ, Aburahma A, Ascher E, Eskandari M, Faries P, Lal BK; Society for Vascular Surgery. Updated Society for Vascular Surgery guidelines for management of extracranial carotid disease: executive summary.


Updated Society for Vascular Surgery guidelines for management of extracranial carotid disease: executive summary. J Vasc Surg. 2011;54:832 836. doi: 10.1016/j.jvs.2011.07.004 521. Carotid Stenting Guidelines Committee: an Intercollegiate Committee of the RACP, RACS AND RANZCR. Guidelines for patient selection and performance of carotid artery stenting. Intern Med J. 2011;41:344 347. 522. Sheffet AJ, Roubin G, Howard G, Howard V, Moore W, Meschia JF, Hobson RW 2nd, Brott TG. Design of the Carotid Revascularization Endarterectomy vs. Stenting Trial (CREST). Int J Stroke. 2010;5:40 46. 523. Latchaw RE,Alberts MJ, Lev MH, Connors JJ, Harbaugh RE, Higashida RT, Hobson R, Kidwell CS, Koroshetz WJ, Mathews V, et al; on behalf of the American Heart Association Council on Cardiovascular Radiology and Intervention, Stroke Council, and the Interdisciplinary Council on Peripheral Vascular Disease. Recommendations for imaging of acute is- chemic stroke: a scientific statement from theAmerican HeartAssociation. 524. European Stroke Organisation Executive Committee and ESO Writing Committee. Guidelines for management of ischaemic stroke and tran- sient ischaemic attack 2008. Cerebrovasc Dis. 2008;25:457 507. doi: HerholzK,MarkusHS,Mart nez-VilaE,NiederkornK,etal;EFNS.EFNS guidelineonneuroimaginginacutestroke:reportofanEFNStaskforce.Eur J Neurol. 2006;13:1271 1283. doi: 10.1111/j.1468-1331.2006.01507.x 526. Limone BL, Baker WL, Mearns ES, White CM, Kluger J, Coleman CI. Common flaws exist in published cost-effectiveness models of phar- macologic stroke prevention in atrial fibrillation. J Clin Epidemiol. 527. HigginsP,MacFarlanePW,DawsonJ,McInnesGT,LanghorneP,LeesKR. Noninvasive cardiac event monitoring to detect atrial fibrillation after ischemic stroke: a randomized, controlled trial. Stroke. 2013;44:2525 528. Miles JA, Garber L, Ghosh S, Spevack DM. Association of transthoracic echocardiography findings and long-term outcomes in patients undergo- ing workup of stroke. J Stroke Cerebrovasc Dis. 2018;27:2943 2950. 529. Haeusler KG, Wollboldt C, Bentheim LZ, Herm J, J ger S, Kunze C, Eberle HC, Deluigi CC, Bruder O, Malsch C, et al. Feasibility and diag- nostic value of cardiovascular magnetic resonance imaging after acute is- chemic stroke of undetermined origin.


Feasibility and diag- nostic value of cardiovascular magnetic resonance imaging after acute is- chemic stroke of undetermined origin. Stroke. 2017;48:1241 1247. doi: 530. Katsanos AH, Giannopoulos S, Frogoudaki A, Vrettou AR, Ikonomidis I, Paraskevaidis I, Zompola C, Vadikolias K, Boviatsis E, Parissis J, et al. The diagnostic yield of transesophageal echocardiography in patients with cryptogenic cerebral ischaemia: a meta-analysis. Eur J Neurol. 535. GaudronM,BonnaudI,RosA,PatatF,deToffolB,GiraudeauB,DebiaisS. Diagnostic and therapeutic value of echocardiography during the acute phase of ischemic stroke. J Stroke Cerebrovasc Dis. 2014;23:2105 2109. 532. Kim SJ, Choe YH, Park SJ, Kim GM, Chung CS, Lee KH, Bang OY. Routine cardiac evaluation in patients with ischaemic stroke and absence of known atrial fibrillation or coronary heart disease: transthoracic ech- ocardiography vs. multidetector cardiac computed tomography. Eur J 533. Adams HP Jr, Bendixen BH, Kappelle LJ, Biller J, Love BB, Gordon DL, Marsh EE 3rd. Classification of subtype of acute ischemic stroke: definitions for use in a multicenter clinical trial: TOAST: Trial of Org 10172 in Acute Stroke Treatment. Stroke. 1993;24:35 41. doi: 534. Galougahi KK, Stewart T, Choong CY, Storey CE, Yates M, Tofler GH. The utility of transoesophageal echocardiography to determine manage- ment in suspected embolic stroke. Intern Med J. 2010;40:813 818. doi: 535. Deleted in proof. 536. de Bruijn SF, Agema WR, Lammers GJ, van der Wall EE, Wolterbeek R, Holman ER, Bollen EL, Bax JJ. Transesophageal echocardiography is superior to transthoracic echocardiography in management of patients of any age with transient ischemic attack or stroke. Stroke. 2006;37:2531 537. Harloff A, Handke M, Reinhard M, Geibel A, Hetzel A. Therapeutic strategies after examination by transesophageal echocardiography in 503 patients with ischemic stroke. Stroke. 2006;37:859 864. doi: 538. Abreu TT, Mateus S, Correia J. Therapy implications of transtho- racic echocardiography in acute ischemic stroke patients. Stroke. 539.


Therapy implications of transtho- racic echocardiography in acute ischemic stroke patients. Stroke. 539. Vitebskiy S, Fox K, Hoit BD. Routine transesophageal echocardiography fortheevaluationofcerebralemboliinelderlypatients.Echocardiography. 540. Kim JT, Park MS, Choi KH, Cho KH, Kim BJ, Han MK, Park TH, Park SS, Lee KB, Lee BC, et al. Different antiplatelet strategies in patients with new ischemic stroke while taking aspirin. Stroke. 2016;47:128 134. 541. Lee M, Wu YL, Saver JL, Lee HC, Lee JD, Chang KC, Wu CY, Lee TH, Wang HH, Rao NM, et al. Is clopidogrel better than aspirin following breakthrough strokes while on aspirin? A retrospective cohort study. BMJ Open. 2014;4:e006672. doi: 10.1136/bmjopen-2014-006672 542. Aronow HD, Novaro GM, Lauer MS, Brennan DM, Lincoff AM, Topol EJ, Kereiakes DJ, Nissen SE. In-hospital initiation of lipid-low- ering therapy after coronary intervention as a predictor of long-term uti- lization: a propensity analysis. Arch Intern Med. 2003;163:2576 2582. 543. Stead LF, Koilpillai P, Fanshawe TR, Lancaster T. Combined phar- macotherapy and behavioural interventions for smoking ces- sation. Cochrane Database Syst Rev. 2016;3:CD008286. doi: 544. Stead LF, Koilpillai P, Lancaster T. Additional behavioural support as an adjunct to pharmacotherapy for smoking cessation. Cochrane Database Syst Rev. 2015:CD009670. doi: 10.1002/14651858.CD009670.pub3


4/28/23, 4:25 PM Stroke Prevention in Women: From Young Adulthood to Older Age - Professional Heart Daily | American Heart Association ADVERTISEMENT Stroke Prevention in Women: From Young Adulthood to Older Age Last Updated: June 13, 2022 Disclosure: Dr. Braun has an NIH grant related to physical activity, she is on the Speaker s Bureau for Practice Point, and she serves on Advisory Boards for Up- To-Date and Sanofi. Pub Date: Thursday, Feb 06, 2014 Author: Lynne Braun, PhD, CNP, FAHA, FAAN Affiliation: Rush University Medical Center and College of Nursing, Chicago Illinois View the summary for Guidelines for the Prevention of Stroke in Women Stroke is the fourth leading cause of death in women. Given that women live longer than men, women who survive a stroke and have residual physical and cognitive deficits will outnumber men. Increasingly strokes occur in younger women as well, which is devastating for young stroke survivors and their families. The Guidelines for the Prevention of Stroke in Women is the first guideline to provide emphasis on risk factors unique to women (such as hormonal factors, pregnancy, and childbirth) and risk factors that more commonly occur in women, including migraine with aura, obesity and metabolic syndrome, and atrial fibrillation. The writing group provides evidence-based recommendations that are unique to women and, of equal importance, identifies gaps in knowledge where additional research is needed to better assess risk and improve strategies for stroke prevention in women. The authors wish not only to improve the understanding of clinicians and researchers about stroke risk and prevention in women, but also to empower women to learn about their risk and how to reduce their chances of having a stroke.


The authors wish not only to improve the understanding of clinicians and researchers about stroke risk and prevention in women, but also to empower women to learn about their risk and how to reduce their chances of having a stroke. Although women benefit from drug therapies for hypertension similarly as men, fewer treated women achieve blood pressure control compared to men. Further research should uncover reasons for why this is the case, e.g., less intense treatment in women, inappropriate drug choices, lack of compliance, treatment resistance, biological factors that account for hormonal status, and perhaps others, Pregnancy-related hypertension is the leading cause of both hemorrhagic and ischemic stroke in pregnant and postpartum women. Women with pregnancy-related complications (pre-eclampsia, gestational diabetes, pregnancy-induced hypertension) have a substantially higher risk for future cardiovascular disease and stroke. Prospective studies in diverse populations are needed to discern whether pre-pregnancy risk factors or pregnancy- associated risk factors predispose women to subsequent risk of stroke. Additionally, there is need for studies in women who have had pregnancy complications to understand the trajectory of the development of cerebrovascular disease, and then to develop screening, risk stratification, and preventive strategies. The guidelines provide specific recommendations for the prevention and treatment of pre-eclampsia and pregnancy-related hypertension. Although only a Class IIa, Level of Evidence C recommendation, guidelines suggest that all women are evaluated for a history of pre- eclampsia/eclampsia and to document this history as a risk factor, then to evaluate and treat cardiovascular and stroke risk factors (hypertension, obesity, smoking, dyslipidemia). This is particularly important for those providers from whom women seek healthcare, such as primary care providers and obstetrician/gynecologists. Stroke from central venous and sinus thrombosis (CVT) is remarkably more common in women, and has been related to hormonal factors (contraceptive use, pregnancy) and thrombophilia.


Stroke from central venous and sinus thrombosis (CVT) is remarkably more common in women, and has been related to hormonal factors (contraceptive use, pregnancy) and thrombophilia. The guidelines provide recommendations for screening, testing for prothrombotic conditions, and anticoagulation for women with CVT and a history of CVT. The overall stroke risk is low from hormonal contraception; however, certain subgroups of women may be at higher risk for stroke, including women who are older, smoke cigarettes, have hypertension, diabetes, obesity, hypercholesterolemia, and prothrombotic mutations. Additional research is needed to learn about subgroups of women at risk for hemorrhagic stroke with oral contraceptive use, with respect to age, race/ethnicity, genetics, and parity. Research should also assess the value of biomarkers of endothelial dysfunction during the course of oral contraceptive use and arterial thrombotic event. The guidelines advocate for blood pressure evaluation prior to hormonal contraceptive initiation as well as the treatment of stroke risk factors among oral contraceptive users. Oral contraceptives should not be given to women who smoke cigarettes or those with prior thromboembolic events. Studies of the association between age at menopause or premature menopause and stroke risk suggest an increased risk of stroke with earlier onset of menopause, but results are inconsistent. Additional research is necessary to fully discern the impact of onset of menopause on stroke risk. An increase in stroke risk is associated with the use of hormone therapy in standard formulations of CEE/MPA as well as the use of SERMs. Additional studies are needed to draw conclusions about long-term hormone therapy use when initiated in perimenopausal women or postmenopausal women younger than 50 years of age. Prospective randomized trials of alternate forms of hormone therapy are ongoing.


Prospective randomized trials of alternate forms of hormone therapy are ongoing. As stated in previous guidelines, neither hormone therapy nor SERMs should be used for the primary or secondary prevention of stroke. Migraine with aura is associated with an increased risk for ischemic and hemorrhagic stroke in women, especially in women under the age of 55 years. Data are insufficient to recommend specific strategies to treat migraine while lowering stroke risk. However, since an association exists between migraine frequency and stroke risk, guidelines support treatments to reduce migraine frequency. Smoking cessation is strongly recommended for women with migraine headaches with aura. Obesity, abdominal obesity, and metabolic syndrome are independent risk factors for stroke; however, there is no clear evidence that obesity has a stronger impact on stroke risk and stroke outcomes in women compared to men. On the other hand, studies show that metabolic syndrome imparts a higher stroke risk in women and accounts for more stroke events in women than in men. Adherence to healthy lifestyle behaviors (maintaining a normal body mass index, eating a diet rich in fruits and vegetables, drinking a moderate amount of alcohol, abstaining from smoking, exercising regularly) has been shown to reduce stroke incidence in women and improve stroke outcomes in both men and women. Guidelines recommend healthy lifestyle practices for primary stroke prevention in women with cardiovascular and stroke risk factors. Further research is needed to develop lifestyle interventions tailored for women that are effective for primary and secondary stroke prevention. Atrial fibrillation is a major risk factor for stroke, and the risk of stroke from atrial fibrillation increases with age. More women over the age of 75 years have atrial fibrillation compared to men. Anticoagulation is effective in reducing stroke risk.


More women over the age of 75 years have atrial fibrillation compared to men. Anticoagulation is effective in reducing stroke risk. Risk stratification tools, such as CHADS and CHADS-VASc, are useful for guiding clinicians in the decision to initiate anticoagulation therapy. New oral anticoagulants are efficacious alternatives to warfarin for stroke prevention, but research is needed to determine the appropriate dose in older women with a lower weight or women with comorbidities such as renal disease. Guidelines recommend the use of risk stratification tools for patients with atrial fibrillation that account for age and sex differences in the incidence of stroke. Primary care clinicians should actively screen women over the age of 75 years for atrial fibrillation using pulse taking followed by ECG as appropriate. New oral anticoagulants are recommended alternatives to warfarin in women with atrial fibrillation at increased stroke risk according to CHADS-VASc. Oral anticoagulation is not recommended for women age 65 years and younger who have atrial fibrillation without other stroke risk factors; antiplatelet therapy is a reasonable option for selected low-risk women. 4/28/23, 4:25 PM Stroke Prevention in Women: From Young Adulthood to Older Age - women with depression are at greatest risk for stroke. In clinical trials of primary and secondary stroke prevention, women need to be included in adequate numbers for preplanned subgroup analysis to examine sex differences. Additional research is needed to determine the benefits and risks of carotid procedures in women with asymptomatic high-grade stenosis and symptomatic moderate (50% to 69%) stenosis. Women with asymptomatic carotid stenosis should be assessed and treated for other stroke risk factors with lifestyle changes and medical therapies. The guidelines include several recommendations regarding the appropriate use of carotid endarterectomy.